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Classical Hodgkin Lymphoma (cHL) comprises a unique cancer where the 
microenvironment accounts for 99 % of the whole tumour mass. In cHL 
dissemination involves functionally neighbouring lymph nodes but the underlying 
mechanisms for the spread of lymphoma cells are poorly understood. This thesis 
aims at characterizing cHL cell migration, invasion and pro-angiogenic properties 
as well as at identifying the underlying oncogenic pathways.  
Herein, it is shown that cHL cell migration, invasion and adhesion depend on 
autocrine WNT signalling as revealed by the inhibition of WNT secretion with 
porcupine inhibitors Wnt-C59/IWP-2 but also by targeting canonical WNT 
signalling. Time-lapse studies identified an amoeboid type of cell migration 
modulated by WNT5A as well as by lymphocyte enhancer-binding factor 1 (LEF-1) 
and β-catenin in a 3D cell culture model. Application of recombinant WNT5A, 
WNT5A overexpression and WNT5A receptor binding inhibition by Box5 affected 
cHL cell migration. Among the diverse WNT pathways, the WNT5A-FZD5-DVL3-
RHOA cascade and basal canonical WNT signalling are regulators of cHL cell 
motility. In addition to these mechanistic insights into the in vitro role of WNTs, 
global gene expression data revealed increased WNT5A and LEF-1 expression in 
primary cHL cells in comparison to normal B-cell subsets and other lymphomas.  
The pro-angiogenic potential of cHL cells was revealed by sprouting and vascular 
tube formation assays of endothelial cells. In that context, LEF-1 and β-catenin 
regulated the secreted VEGFA levels of cHL cells. Importantly, VEGFA gene 
expression is prognostic for cHL. Furthermore, impaired WNT secretion or 
canonical WNT signalling as well as WNT5A stimulation had an impact on 
lymphoma development in the chick chorio-allantoic membrane (CAM) assay. The 
vasculature network was significantly reduced after inhibition of WNT secretion by 
Wnt-C59 or canonical WNT pathway inhibition.  
Therefore, a model is proposed where WNT signalling plays an important role in 
regulating cHL progression-associated processes. 
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Cancer is one of the leading cause of death worldwide and its impact will further 
rise due to the growing and ageing world population (Torre et al, 2015). Malignant 
lymphomas comprise a heterogeneous group of more than 30 subtypes divided 
into Non-Hodgkin (NHL) and Hodgkin Lymphoma (HL) (Swerdlow et al, 2008). 
Lymphoma spread often correlates with poor prognoses and challenges therapy 
options (Armitage, 1993; Gospodarowicz & Sutcliffe, 1995; Yamamoto et al, 2010; 
Guermazi et al, 2001). In contrast to the metastasis process of solid cancers 
lymphoma dissemination and the underlying signalling mechanisms are only 
poorly understood. Therefore, an improved understanding of those mechanisms 
regulating lymphoma migration and their interaction with endothelial and lymphatic 
cells are needed.   
1.1 Classical Hodgkin Lymphoma (cHL) 
In 1832 Thomas Hodgkin described for the first time the “morbid appearances of 
the absorbent glands and spleen” in seven patients (Hodgkin, 1832). The 
observed lymphoid malignancy is named after him. HL is classified into the 
classical Hodgkin Lymphoma (cHL), which accounts for 95 % of HL cases, and the 
less frequent nodular lymphocyte-predominant HL (NLPHL) (Lukes & Butler, 1966; 
Eichenauer et al, 2014). Based on histology cHL is further subdivided into the 
nodular sclerosis (60 %), mixed cellularity (30 %), lymphocyte-rich and 
lymphocyte-depleted subtype (Swerdlow et al, 2008). In the European Union the 
annual incidence of HL is 2.3 cases and the corresponding mortality rate 0.4 cases 
per 100000 people (Ferlay et al, 2013). The age distribution at diagnosis is 
bimodal with a first incidence peak seen in young adults (20-35 years) and a 
second peak in people aged 55 years or older in the industrialized countries. While 
younger people are more often affected by the nodular sclerosis subtype, the 
mixed cellularity subtype occurs at higher frequencies in patients older than 30 
years (Thomas et al, 2002).  
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1.1.1 Histological and molecular characteristics of cHL 
In cHL the large malignant cells comprise mononuclear Hodgkin and bi- or 
multinuclear Reed Sternberg cells, which have been described first around 1900 
and are called HRS cells henceforth (Sternberg, 1897; Reed, 1902). HRS cells just 
account for 0.2-2 % of the whole tumour mass and are embedded in a background 
of reactive lymphatic stroma, including B- and T-cells, plasma cells, eosinophils, 
macrophages and granulocytes (Küppers, 2009; Liu et al, 2014) (see also chapter 
1.1.3). The origin of HRS cells has been discussed for years but the detection of 
clonal and somatically mutated Ig heavy- and light-chain gene rearrangements 
support the view that HRS cells arise from germinal centre B-cells that escaped 
from apoptosis (Trümper et al, 1993; Küppers et al, 1994; Kanzler et al, 1996b; 
Marafioti et al, 2000). In only rare cases HL is derived from T-cells (Müschen et al, 
2000; Seitz et al, 2000). HRS cells are predominantly found in the interfollicular 
zone or, less frequently, in the follicular mantle zone of lymph follicles in nodular-
infiltrated lymph nodes (Küppers et al, 2012). One characteristic of HRS cells is 
the expression of CD30, a receptor of activated B- and T-cells (Stein et al, 1983, 
1985). Importantly, HRS cells lost the typical B-cell identity by global 
reprogramming of several B-cell genes like B-Cell Linker (BLNK) (Schwering et al, 
2003). HRS cells rather coexpress a mixture of various hematopoietic lineage 
markers like T-cell, B-cell, myeloid cell, dendritic cell or NK cell markers (Foss et 
al, 1999; Takahashi et al, 1995; van den Berg et al, 1999; Sahin et al, 2002). In 
industrialized countries HRS cells are infected by the Epstein-Barr virus (EBV) in 
40 % of all cases but those cases are predominantly found in the mixed-cellularity 
and the lymphocyte-depleted HL subtype (Kapatai & Murray, 2006). In paediatric 
cases of developing countries EBV infections are found in about 90 % of HL cases 
and if patients suffer from the acquired immunodeficiency syndrome (AIDS) a 
simultaneous EBV infection can be found in almost all HL cases (Dolcetti et al, 
2001; Kapatai & Murray, 2006). EBV mediates the survival of germinal centre 
B-cells by mimicking and thus controlling CD40 signalling (Kilger et al, 1998).  
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1.1.2 Deregulated signalling pathways in cHL 
For the last 20 years progress has been made in understanding molecular 
pathway deregulations of cHL cells. A simplified overview on some known 
pathway deregulations at several pathway levels is presented in Figure 1. 
Deregulations due to genetic lesions have mainly been associated with the nuclear 
factor kappa-light-chain-enhancer of activated B-cells (NF-κB) and Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathway. In 
approximately half of the cHL cases a gain-of-function mutation or amplifications 
involve V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog (REL), a 
NF-κB transcription family member (Barth et al, 2003; Joos et al, 2002). In the 
JAK/STAT pathway gains of JAK2 or inactivating point mutations of a negative 
JAK/STAT signalling regulator, suppressor of cytokine signalling 1 (SOCS1), are 
very frequent (Joos et al, 2000; Weniger et al, 2006). In addition to genetic lesions 
also autocrine and paracrine signalling cascades play a role for aberrant pathway 
activations in cHL. Several STAT factors including STAT3, STAT5A/B and STAT6 
are activated due to autocrine interleukin signalling (Kube et al, 2001; Kapp et al, 
1999; Scheeren et al, 2008; Skinnider et al, 2002; Lamprecht et al, 2008). Next to 
NF-κB and JAK/STAT signalling other deregulated or constitutively active 
pathways are the mitogen-activated protein kinase (MAPK)/ERK and 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. In MAPK/ERK 
signalling ERK1, ERK2 and ERK5 and in PI3K signalling v-akt murine thymoma 
viral oncogene homolog 1 (AKT) are constitutively activated (Nagel et al, 2007; 
Zheng et al, 2003; Dutton et al, 2005). The biological outcome of these aberrant 
activities in multiple pathways for cHL cells is usually linked to cell proliferation and 
cell survival but lacks information on migration or invasion processes.  




Figure 1: Schematic overview of some known deregulated signalling pathways in cHL cells. 
The different pathways are encoded in the following colours: NF-κB pathway in pink, MAPK 
pathway in blue, JAK/STAT pathway in green and PI3K pathway in orange. Pathway members with 
deregulations in cHL cells are highlighted with red flashes. References for the shown pathway 
modulations are as follows: (1) (Otto et al, 2012; Steidl et al, 2010b) (2) (Fiumara et al, 2001) (3) 
(Horie et al, 2002) (4) (Kato et al, 2009; Schmidt et al, 2010) (5) (Krappmann et al, 1999; Cabannes 
et al, 1999) (6) (Joos et al, 2002; Barth et al, 2003) (7) (Zheng et al, 2003) (8) (Kube et al, 2001; 
Skinnider et al, 2002) (9) (Dutton et al, 2005) (10) (Tiacci et al, 2012).  
1.1.3 The role of the microenvironment in cHL    
The tumour microenvironment can initiate and promote cancer progression 
including tumour growth, spread and therapy resistance (Hanahan & Weinberg, 
2011). In the cHL tumour mass the malignant HRS cells highly depend on signals 
and cross talks with their surrounding cells (Aldinucci et al, 2010; Liu et al, 2014). 
HL cells actively secrete chemokines to shape their microenvironment (Maggio et 
al, 2002). Chemokines as chemokine (C-C Motif) ligand 5 (CCL5), CCL17/TARC 
or chemokine (C-X-C Motif) ligand 10 (CXCL10) are secreted by HRS cells to 
attract especially T-cells (Aldinucci et al, 2008; van den Berg et al, 1999; 
Teichmann et al, 2005; Vockerodt et al, 2005). Another example is CCL28, which 
is secreted to attract eosinophils and plasma cells to the cHL tumour infiltrate 
(Hanamoto et al, 2004). Importantly, the lymphoma-microenvironmental interplay 
does not only involve active secretion processes of cHL cells but also tumour-
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promoting behaviour of the surrounding cells. Until now the impact of surrounding 
cells has been studied for T-cells, macrophages, natural killer cells, fibroblasts, 
mast cells, eosinophils and dendritic cells (Pinto et al, 1996; Molin et al, 2001; 
Carbone et al, 1995; Schreck et al, 2009; Ohshima et al, 2002; Jundt et al, 1999). 
Especially small CD4+ T-cells, that surround the malignant cHL cells in rosettes-
like structures, are in close contacts with the HRS cells (Küppers, 2009). These 
CD4+ T-cells express increased CD40 ligand and thus may contribute to cell 
survival in cHL cells (Carbone et al, 1995; Annunziata et al, 2000). In addition, 
mast cells and eosinophils secrete CD30 ligand thereby supporting as well cHL 
cell survival (Pinto et al, 1996; Molin et al, 2001). Mast cells can also promote cHL 
cell proliferation in vitro and neovascularization in vivo (Mizuno et al, 2012). The 
presence of microenvironmental cells has also already been adopted for 
prognosis. Outcome of cHL has been adversely correlated with the presence of 
CD68 and CD163 expressing macrophages/monocytes in cHL tumours (Kamper 
et al, 2011). Nevertheless the prognostic value of CD68 staining in cHL samples is 
still discussed (Klein et al, 2014; Agur et al, 2015). These data further underline 
the importance of a particular microenvironment for cHL cell survival.  
Notably, studies highlighting Hodgkin Lymphoma-endothelial cell interactions are 
rare. But regarding AML, prostate and breast carcinoma, the tumour-endothelial 
crosstalk has been proven to influence carcinogenesis and tumour outcome and 
might therefore be of interest also for cHL (Cogle et al, 2014; Zhang et al, 2013; 
Nagaraj et al, 2015; Comito et al, 2014). 
1.1.4 Therapy options, challenges and limitations 
Over the last 50 years the therapy options for cHL patients improved remarkably 
from an incurable disease to a curation rate of 80 % with modern therapies 
(Canellos et al, 2014). For early-stage patients usually a combined modality 
treatment of the standard chemotherapy regiment doxorubicin, bleomycin, 
vinblastine, and dacarbazine (ABVD) and radiation therapy is used leading to a 
5-year overall survival of more than 90 % (Armitage, 2010). Next to ABVD 
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chemotherapy the dose enhanced BEACOPPescalated (bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) 
regiment is a treatment possibility for advanced-stage cHL patients albeit its higher 
toxicity is limiting especially for older patients (Engert et al, 2009). If such first-line 
treatment modalities fail, therapy of relapsed cHL cases involves platinum-based 
chemotherapy, followed by high-dose chemotherapy and autologous stem cell 
transplantation which still leads at best to curation rates of 50-60 % (Clavio et al, 
2005; Santoro et al, 2007). Despite these successful approaches to cure cHL 
future challenges will be to improve treatment modalities for advanced-stage and 
relapsed cases and to reduce delayed treatment toxicities without compromising 
the current survival rates. Since cHL concerns to a majority teenager and young 
adults (see chapter 1.1) therapy toxicities can diminish life quality and severely 
limit the expected life span. One serious consequence of high-dose chemotherapy 
and combined radiotherapy is the increased incidence of secondary malignancies 
which concerns especially leukaemia, breast and colon carcinoma (Aleman et al, 
2003; Hodgson et al, 2007; Schellong et al, 2014). Moreover, patients report that 
long-term life quality is diminished compared to matched control people mainly 
due to dyspnoea and symptom of fatigue (Brandt et al, 2010; Rüffer et al, 2003). 
These side-effects of high-dose chemotherapy, the increase in secondary 
malignancies and decrease in life quality, further underline the request for more 
targeted and less toxic therapy modalities.  
Therefore, new biological targets are searched for cHL therapy. Since the 
expression of CD30 is characteristic for the malignant HRS cells (see chapter 
1.1.1) a tubulin inhibitor, monomethyl auristatin E (MMAE), has been coupled to a 
mononuclear anti-CD30 antibody to target the HRS cells in a more specific 
manner (Katz et al, 2011; Francisco et al, 2003). This new antibody drug 
conjugate, brentuximab vedotin (BV), was approved in the European Union for 
cHL patients with front-line therapy failures (Gravanis et al, 2016; Younes et al, 
2012). Nevertheless new approaches targeting the cHL microenvironment and 
diminishing cHL spread without the need of radiotherapy are discussed for years. 
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1.2 Processes associated with lymphoma progression 
One characteristic of cancer progression is the cellular ability to move and to 
invade into surrounding tissues. But for lymphomas the starting point is a different 
one regarding their specific cellular characteristics. Since lymphoma cells are 
derived from highly motile but strictly regulated immune cells their dissemination 
capacity strongly resembles physiologically conserved lymphocyte migration 
patterns (Pals et al, 2007). Nevertheless lymphoma dissemination displays a 
general challenge for therapy and long-term survival and its underlying 
mechanisms need to be investigated. Since HL growth in vivo requires crosstalks 
and interactions with the microenvironment, these interactions may also contribute 
to lymphoma progression (Liu et al, 2014). Especially the interaction and 
manipulation of endothelial cells may induce tumour angiogenesis thus permitting 
tumour growth, pathological tumour metabolism, inflammation and tumour cell 
invasion and dissemination (Wang et al, 2015). Despite this impact for lymphoma 
progression signalling pathways regulating angiogenesis in HL have only rarely 
been studied so far. 
1.2.1 Migration and invasion processes 
The movement patterns of lymphocytes depend on their specific maturational 
stage and are regulated by fine-tuned mechanisms in order to modulate immune 
reactions and wound healing (Butcher & Picker, 1996; Kunkel & Butcher, 2002). 
Aberrations in the corresponding migration pathways have been intensively 
studied mainly for solid tumour promotion (Wood et al, 2014). In contrast 
lymphoma dissemination in general is thought to depend on conserved homing 
programs and receptor expression patterns responsible for the regulation of 
lymphocyte trafficking (Pals et al, 1989, 2007). Both, physiological B-cell migration 
as well as lymphoma dissemination, is regularly observed to sites of chronic 
inflammation underlining the different mechanism of lymphoma dissemination 
compared to the metastasis of solid tumours (Shetty et al, 2012; Sakai & 
Kobayashi, 2015). For example, CLL or MCL originate from small recirculating 
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lymphocytes and are associated with high systemic dissemination rates at 
presentation as well as high cell migration rates in vitro (Lopez-Giral et al, 2004). 
In contrast Burkitt lymphoma (BL) and diffuse large B-cell lymphomas (DLBCL) are 
related to actively proliferating and differentiating lymphocytes and are more often 
initially detected at their sites of origin (Matasar & Zelenetz, 2008; Pals et al, 
2007). Consequently, migration capability may not directly reflect tumour 
progression but can be seen as conserved physiological behaviour of the cell of 
origin.  
In cHL the accumulation of abundant reactive infiltrates is a result of locally 
produced chemokines and comparative analyses between different chemokines 
revealed different migration preferences of HL cells (Höpken et al, 2002; Aldinucci 
et al, 2008; van den Berg et al, 1999). Although these studies could show, that HL 
cells themselves migrate in a chemokine-guided manner, they missed a detailed 
analysis of the impact of migration and invasion properties for HL tumours and the 
mechanisms behind. But a deeper knowledge of cHL migration mechanisms would 
be necessary to understand also dissemination processes. For example, it has 
been shown that CLL cells migrated across high endothelial venules (HEVs) into 
nodes in response to CCL19 and CCL21 (Till et al, 2002). Endothelial cells of 
HEVs present high levels of the chemokine CCL19 and CCL21 at their luminal 
faces (Baekkevold et al, 2001). Consequently CCL19/CCL21-mediated 
chemotaxis might also be of interest for lymphoma studies. 
Migration types in general are subdivided into at least three different forms: the 
mesenchymal and amoeboid single cell migration and the collective cell migration 
(Friedl & Wolf, 2003b). The mesenchymal migration type of single epithelial cancer 
cells requires surface proteases to degrade and remodel the extracellular matrix 
(ECM) in order to migrate forward via leading pseudopod formation and retraction 
of the cell rear (Hay, 1990; Wolf et al, 2003). The sequence of collective cell 
migration is similar, but several cells are interconnected by cadherins and gap 
junctions (Graeber & Hülser, 1998; van Kempen et al, 2000). Amoeboid migration 
has been observed in leukocyte, haematopoietic stem cells and several cancer 
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cells (Friedl et al, 2001; Francis et al, 2002; Wang et al, 2002). For amoeboid cell 
migration ECM barriers are not degraded but circumnavigated or the high cell 
deformability allows the cell to squeeze and glide through smallest pores (Friedl & 
Wolf, 2003a). Consequently, short-lived interactions with the matrix replace stable 
focal contacts in the amoeboid migration type, thus allowing very fast and efficient 
movements. For instance, the migration of a T-cell lymphoma was not impeded by 
protease inhibitors underlying the independence from matrix metalloproteinases 
secretion (Krüger et al, 2001). 
1.2.2 Induction of angiogenesis 
According to solid cancers, growth and progress of B-cell lymphoproliferative 
diseases is also thought to depend on access to blood vessels, including new 
vessel formation (Vacca et al, 1995). For vasculogenesis endothelial cells are 
often switched from resting to active cells by a microenvironmental increase of 
positive angiogenesis regulators like vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), angiopoietins (Ang) or platelet derived growth factor 
(PDGF). Tumour cells actively influence this process by tipping the net balance 
between positive and negative angiogenesis regulators towards the pro-
angiogenic ones (Neufeld et al, 2001). Then initial angiogenesis events involve the 
migration of tip cells at the vessel leading front causing vessel sprouting. 
Afterwards, a lumen is formed and the stabilization and maturation processes start 
including adhesion to the underlying matrix, basement membrane generation and 
blood flow (Carmeliet & Jain, 2011). Since tumour cells create an imbalance 
between angiogenesis regulators, tumour vessels are characterized by an unusual 
leakiness involving poor coverage by vascular supportive cells, reduced 
functionality, perfusion and a high remodelling potential (Jain, 2005). But how and 
by which signalling pathway HRS cells influence and are influenced by endothelial 
cells is still widely unclear. 
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1.3 WNT signalling 
One pathway that has been described in tumour metastasis as well as 
angiogenesis processes is the WNT signalling cascade (Kurayoshi et al, 2006; 
Zhang et al, 2001). WNT signalling is important for embryonic development, self-
renewal of some adult tissues but it is also involved in tumourigenesis e.g. in 
colorectal cancer (Liu et al, 1999; Wang & Wynshaw-Boris, 2004; Reya et al, 
2003; Groden et al, 1991; Liu et al, 2000; Ge & Wang, 2010). To our knowledge 
WNT signalling has never been investigated in HLs and only marginally in 
aggressive Non-Hodgkin lymphomas (NHLs) (Walther et al, 2013). Nevertheless, 
NHL related to small recirculating lymphocytes such as chronic lymphocytic 
leukaemia (CLL) or mantle cell lymphoma (MCL) have already been described to 
depend on WNT signalling (Kaucká et al, 2013; Gelebart et al, 2008; Rizzatti et al, 
2005; Gutierrez et al, 2010; Gandhirajan et al, 2010; Tandon et al, 2011).  
In 1982 the first WNT ligand, formerly called Int1, has been discovered as proto-
oncogene in mice (Nusse & Varmus, 1982). Since then 19 highly conserved 
different WNT ligands and 15 WNT receptors and co-receptors have been 
identified in humans (Niehrs, 2012). The combination of WNT ligand, WNT 
receptor and the particular cellular context finally determines activation of 
downstream pathways. In general, the β-catenin-dependent, so called canonical, 
pathway is distinguished from β-catenin-independent, so called non-canonical, 
pathways (Figure 2). Despite the complexity of combination possibilities several 
preferences for WNT ligands and receptors have been described. For example, 
WNT1, WNT3A and WNT8 are supposed to activate predominantly the canonical 
WNT pathway while WNT5A and WNT11 mainly activate non-canonical WNT 
pathways (Kikuchi et al, 2011). In addition, low-density lipoprotein receptor-related 
protein 5 (LRP5) and LRP6 are supposed to be primarily involved in canonical 
WNT signalling and receptor tyrosine kinase-like orphan receptors 1/2 (ROR1/2) in 
non-canonical WNT signalling (Tamai et al, 2000; Hsieh, 2004). In contrast, 
Frizzled (FZD) receptors and Dishevelled (DVL) adaptor proteins appear to be 
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involved in all three signalling cascades (Huang & Klein, 2004; Gao & Chen, 
2010).  
 
Figure 2: Overview of β-catenin-dependent and -independent WNT pathways. (A) Planar cell 
polarity (PCP) pathway activates small GTPases (RHOA, RAC1) to induce mainly cell polarity and 
motility through actin polymerization. (B) The canonical, β-catenin-dependent, WNT pathway 
destabilizes the β-catenin destruction complex upon activation thus enabling β-catenin to 
translocate to the nucleus and to induce the corresponding target gene transcription. (C) Another 




signalling can activate CDC42 to 
induce actin polymerization like the PCP pathway or activate the nuclear factor of activated T-cells 
(NFAT) for gene transcription regulation. The Ca
2+
-dependent WNT pathway can block the 
β-catenin-dependent pathway at several levels. This scheme has been taken from “The complex 
world of WNT receptor signalling” (Niehrs, 2012).  
Since WNT function depends on its local concentration, the secretion mechanism 
of WNT ligands, has been investigated as an important control point of WNT 
signalling strength (Zecca et al, 1996). In order to act as gradient morphogens 
WNT ligands need to be post-translationally modified involving palmitoylation 
which is essential for extracellular transport and binding to FZD receptors (Janda 
et al, 2012; Coombs et al, 2010). Porcupine is an o-acyltransferase resident at the 
membrane of the endoplasmic reticulum that mediates the palmitoylation of WNT 
ligands (Proffitt & Virshup, 2012; Takada et al, 2006). At the Golgi apparatus 
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palmitoylated WNT ligands can bind to WNTLESS (WLS) and are escorted to the 
plasma membrane (Kurayoshi et al, 2007; Hausmann et al, 2007). Recently it has 
been shown that active WNT ligands can be secreted on extracellular vesicles 
(EVs) (Gross et al, 2012). 
A promising target of the WNT ligand secretion pathway is the enzyme porcupine 
which can be blocked by small molecules (Chen et al, 2009). Porcupine inhibition 
caused reduced viability and proliferation rates in several tumour entities like 
mammary tumours or gastric cancer (Proffitt et al, 2013; Mo et al, 2013). 
1.3.1 Canonical WNT signalling 
Canonical WNT signalling depends on the activation and subsequent nuclear 
translocation of β-catenin. The evolutionally conserved protein β-catenin belongs 
to the armadillo family of proteins and acts as adaptor protein for intracellular 
adhesion and as transcriptional regulator of the canonical WNT pathway (Peifer, 
1993; Su et al, 1993; Hayashida et al, 2005).  
In the absence of an activating WNT ligand, the β-catenin destruction complex, 
which is composed of glycogen synthase kinase 3 (GSK3), casein kinase 1 (CK1), 
Axin and adenomatous polyposis coli (APC), mediates the phosphorylation of 
β-catenin (Kimelman & Xu, 2006). This phosphorylation of β-catenin serves as 
signal for ubiquitylation by SKP1–cullin 1– F-box E3 ligase and the subsequent 
proteasomal degradation of β-catenin in the cytosol (Wu et al, 2003). Upon WNT 
ligand binding to the complex of FZD receptors and the LRP5/6 co-receptors DVL 
proteins are phosphorylated and the destruction complex is destabilized. Activated 
DVL is thought to phosphorylate the co-receptor LRP6 and to associate with Axin 
thus inactivating the destruction complex (Kishida et al, 1999; Zeng et al, 2008). 
This causes the accumulation and subsequent nuclear translocation of β-catenin 
(Figure 2) (Polakis, 1999; Tamai et al, 2000). In the nucleus β-catenin binds to a 
Transcription Factor (T-Cell Specific, HMG-Box)/lymphocyte enhancer-binding 
factor 1 (TCF/LEF-1) transcription factor. LEF-1 belongs to the TCF/LEF family of 
transcription factors with a clear homology to HMG group proteins (Travis et al, 
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1991). In the nucleus TCF/LEF-1 binds β-catenin in a core complex with B-cell 
CLL/Lymphoma 9 (BCL9) and Pygopus and regulates the transcription of several 
targets including, amongst others, cyclin D1, C-MYC and matrix 
metalloproteinases (Behrens et al, 1996; Kramps et al, 2002; Shtutman et al, 
1999; Yochum et al, 2008; Yochum, 2011; Brabletz et al, 1999; Wu et al, 2007).  
1.3.2 Non-canonical WNT signalling 
For the non-canonical or β-catenin-independent WNT pathway WNT/FZD 
complexes initiate signalling with the help of heterotrimeric G proteins and DVL to 
regulate the cytoskeleton (planar cell polarity pathway; PCP) or to increase the 
intracellular calcium concentration (calcium-dependent WNT signalling) (Figure 2) 
(Veeman et al, 2003).  
In vertebrates the PCP pathway regulates convergent extension movements of 
epithelial cells, and is of great importance during early embryonic development, 
the gastrulation process, cochlear cell polarity and during neuronal tube 
development and axon guidance (Habas et al, 2001; Dabdoub & Kelley, 2005; 
Goodrich, 2008; Wallingford et al, 2002). The PCP pathway involves DVL, Ras 
Homolog Family Member A (RHOA) and Rho-Associated, Coiled-Coil Containing 
Protein Kinase (ROCK) and was first described as polarity pathway in drosophila 
(Nübler-Jung, 1987; Boutros & Mlodzik, 1999; Strutt et al, 1997; Winter et al, 
2001). Binding of WNTs to their corresponding receptors is associated with the 
activation of one of the three DVL molecules (Wong et al, 2003; Gonzalez-Sancho 
et al, 2004). Thereby DVL binds to FZD receptors via its central PDZ domain and 
gets activated (Wong et al, 2003). Activated DVL forms a complex with the DVL-
associated activator of morphogenesis (DAAM) and RHOA which causes 
activation of RHOA and subsequently of its effector ROCK (Habas et al, 2001; 
Ishizaki et al, 1997).  
One prominent non-canonical WNT is WNT5A. WNT5A has been discovered 
together with other WNTs in mouse development in 1990 (Gavin et al, 1990). 
Soon it emerged that WNT5A plays pivotal roles in germ cell differentiation, 
Introduction    
14 
 
repopulation and maintenance of haematopoietic stem cells and regulation of 
chondrogenesis (Danielson et al, 1995; Nemeth et al, 2007; Hartmann & Tabin, 
2000; Yang et al, 2003). WNT5A encodes two isoforms through an alternative 
exon one (Katoh & Katoh, 2009). WNT ligands bind specifically to FZD receptors, 
which are a distinct group of G-protein-coupled receptors sharing structural 
similarities with chemokine and sphingosine receptors (Schulte & Bryja, 2007). 
Studies on the binding of WNT ligands to FZD receptors revealed the high 
specificity of WNT5A for FZD5 (Dijksterhuis et al, 2015). But depending on the 
particular cellular receptor setting, WNT5A can not only activate calcium-
dependent or PCP non-canonical WNT signalling but also block or activate 
β-catenin-dependent canonical WNT signalling (Mikels & Nusse, 2006). Due to 
this broad spectrum of regulated pathways by WNT5A it is not only associated 
with physiological processes but also with inflammatory disorders like rheumatoid 
arthritis or atherosclerosis and tumourigenesis (Sen et al, 2000; Christman et al, 
2008; Bhatt et al, 2012; Kurayoshi et al, 2006). To target WNT5A an agonist, 
Foxy-5, and the corresponding antagonist, Box5, have been developed (Jenei et 
al, 2009; Blagodatski et al, 2014).  
The calcium-dependent non-canonical WNT signalling involves the activation of 
calcium-sensitive kinase protein kinase C (PKC) and the calcium-responsive 
transcription factor nuclear factor of activated T-cells (NFAT) (Sheldahl et al, 1999; 
Saneyoshi et al, 2002). Since the calcium-dependent pathway is not subject to this 
thesis it will not be introduced in further detail. 
1.3.3 WNT signalling in cancer progression, metastasis and angiogenesis 
The WNT pathway is strictly balanced in physiology and disruptions of this 
homeostasis can directly promote pathogenic processes (Clevers, 2006). The 
dramatic impact of canonical WNT signalling for tumourigenesis has been 
described best for colon carcinoma regarding APC mutations (Nishisho et al, 
1991; Kinzler et al, 1991; Kinzler & Vogelstein, 1996). Axin mutations are often 
found in hepatocellular cancers while mutations of β-catenin have been found 
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amongst others in medulloblastoma, ovarian carcinoma, gastric cancer and also 
colon carcinoma (Satoh et al, 2000; Zurawel et al, 1998; Wright et al, 1999; 
Clements et al, 2002; Morin et al, 1997). High LEF-1 expression is correlated with 
tumourigenesis e.g. in colon cancer, lymphomas, CLL, acute lymphocytic 
leukaemia (ALL), acute myeloid leukaemia (AML) and metastatic melanoma 
(Hovanes et al, 2001; Gelebart et al, 2008; Spaulding et al, 2007; Gutierrez et al, 
2010; Petropoulos et al, 2008; Wang et al, 2005; Simon et al, 2005; Murakami et 
al, 2001).  
Among the various WNT ligands, evidence has accumulated that WNT5A is a key 
player for tumour metastasis by modulating cell motility (Kurayoshi et al, 2006; Qin 
et al, 2015; Klemm et al, 2011). WNT signalling and especially WNT5A have been 
correlated to tumour migration and invasion in several tumour entities like 
hepatocellular carcinoma, gastric cancer or lung cancer bone metastasis (Qin et 
al, 2007; Kurayoshi et al, 2006; Nguyen et al, 2009). Recent studies on CLL and 
multiple myeloma have also revealed an involvement of non-canonical WNT 
signalling in migration and invasion of the disease (Kaucká et al, 2013; Qiang et al, 
2005).  
However, WNT signalling plays not only a role for tumour progression and 
metastasis but also regulates angiogenesis processes. In physiological 
angiogenesis processes WNT signalling has already been shown to be important 
for the developing retina, the placenta and ovaries (Xu et al, 2004; Hsieh et al, 
2005; Luhmann et al, 2005). A direct migration stimulating effect of the canonical 
WNT3A on Human Umbilical Vein Endothelial Cells (HUVECs) has been reported 
by Samarzija et al (Samarzija et al, 2009). In addition, also canonical WNT 
signalling of the tumour cells themselves can regulate angiogenesis. In colonic 
neoplasia canonical β–catenin-dependent WNT signalling has been reported to 
regulate VEGF and therefore angiogenesis in a pre-malignant disease (Zhang et 
al, 2001). 
Since deregulated WNT signalling plays a role in several cancer entities inhibiting 
canonical pathway members is subject of research as well as clinical trials. Among 
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the secreted canonical WNT antagonists the Dickkopf (DKK) protein family is the 
best described (Niehrs, 2006). Both, DKK1 and DKK2, specifically inhibit the 
canonical WNT pathway by antagonizing the co-receptors LRP5/6 (Semënov et al, 
2001; Mao & Niehrs, 2003; Zhu et al, 2012). Nevertheless there is evidence that 
DKK2 can also activate canonical WNT signalling depending on the particular 
cellular context (Wu et al, 2000). In addition, DKK1 levels are elevated in 
oesophageal adenocarcinoma and hepatocellular cancer, leading to the 
hypothesis that aberrant as well as downregulated WNT signalling can ultimately 
cause cancer or other pathogenic processes (Darlavoix et al, 2009; Yu et al, 
2009). The application of small molecules or neutralizing antibodies can provide 
possibilities to restore balanced WNT signalling (NCT02013154; NCT02375880) 
(Zhao et al, 2009). Targeting the β-catenin destruction complex is another attempt 
to downregulate aberrant β-catenin activity in cancer. For years axin inhibition has 
been investigated as auspicious target of canonical WNT signalling. Several 
inhibitors targeting the axin inhibitors, tankyrases, have been chemically designed 
like XAV939 (Novartis) or G007-LK (Roche) but so far none of those was 
approved for clinical trials (Yeh & Peterson, 2009; Lehtiö et al, 2013; Huang et al, 
2009; Lau et al, 2013). Targeting the non-canonical WNT pathway still remains 
difficult since e.g. FZD receptors share high homologies and can function 
interchangeably (Curtin & Lorenzi, 2010). Other inhibitors like Y-27632 targeting 
ROCK are not yet specific enough for clinical trials. 
Of note, there is so far no detailed knowledge about WNT signalling in cHL cells 
despite its impact for the above mentioned lymphoma and leukaemia entities. 
Consequently a deeper understanding of WNT signalling cascades in cHL cells 
could also contribute to the general comprehension of cHL progression and thus 
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Aim of the thesis 
In cHL, the accumulation of reactive infiltrate is a result of locally produced 
chemokines. Although studies could show that cHL cells, too, migrate in a 
chemokine-dependent manner, fundamental questions about the impact of the 
migratory and invasive properties of cHL cells for the microenvironment and for 
tumour motility within the process of dissemination and progression have not yet 
been investigated. 
Lymphoma dissemination in general is thought to depend on conserved homing 
factors and receptors, which regulate lymphocyte trafficking in health and disease 
and thus follows characteristic patterns. Recent studies on CLL and multiple 
myeloma have revealed an involvement of non-canonical WNT signalling in 
migration and invasion of the disease. The underlying signalling mechanism for 
movements towards appropriate chemokine gradients and therefore towards 
favourable niches as well as the manipulation of the own microenvironment of cHL 
cells is subject to this thesis.  
Therefore, the thesis aims at (i) characterizing migration and invasion of cHL cells 
and (ii) at investigating the lymphoma-endothelial interplay in the context of WNT 
signalling. In order to get deeper insight into cHL cell migration properties the 
following questions have to be answered: 
1. How do cHL cells migrate in comparison to other lymphoma cells in defined 
chemokine gradients? 
2. Is autocrine WNT signalling important for cHL cell migration and invasion?  
3. How do PCP and/or β-catenin-dependent WNT signalling contribute to cHL cell 
motility? 
To answer these questions the migration of cHL cells was characterized in 2D and 
3D cell migration models first. The role of WNT signalling was analysed by RNA 
interference-mediated knockdowns of specific pathway components and the 
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application of chemical inhibitors. For confirmation microarray data of cHL patients 
were tested for the expression of particular WNT pathway members.  
To get further insight into the interplay of cHL cells with endothelial cells and the 
impact of WNT signalling the following questions have to be answered: 
1. Do cHL cells possess pro-angiogenic properties? 
2. Does WNT signalling of cHL cells affect the interplay with endothelial cells in 
vitro and in vivo? 
 
Therefore, the initial capacity of cHL cells to induce angiogenesis in vitro and the 
influence of WNT signalling on these processes were measured in vivo in a 
chicken model system. 
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2. Material and Methods 
2.1 Cell lines 
Cell lines used in this study are listed in Table 1. 
Table 1: Cell lines 
Cell line Source Reference 
BL-2 Burkitt Lymphoma (B-cell, EBV-) 
(Bertrand et al, 1981; 
Kube et al, 1995) 
BL-30 Burkitt Lymphoma (B-cell, EBV-) (Philip et al, 1984) 
Carnaval 




HEK293T human primary embryonal kidney cells  
(Graham et al, 1977; 
DuBridge et al, 1987) 
HUVEC 
Human Umbilical Vein Endothelial 
Cells 
primary cells (Lonza, 
Basel, CH) 
JeKo-1 Mantle Cell Lymphoma (B-cell, EBV-) (Jeon et al, 1998) 
Karpas-422 
Diffuse Large B-cell lymphoma (B-cell, 
EBV-) 
(Dyer et al, 1990) 
KM-H2 Hodgkin Lymphoma (EBV-) (Kamesaki et al, 1986) 
L1236 Hodgkin Lymphoma (EBV-) (Wolf et al, 1996) 
L428 Hodgkin Lymphoma (EBV-) (Schaadt et al, 1979) 
L-cell wildtype mouse fibroblasts (Willert et al, 2003) 
L-cell WNT3a 
mouse fibroblasts (stable expression of 
WNT-3A vector, G418 resistance) 
(Willert et al, 2003) 
L-cell WNT5a 
mouse fibroblasts (stable expression of 
WNT-5A vector, G418 resistance) 
(Chen et al, 2003) 
Mino Mantle Cell Lymphoma (B-cell, EBV-) (Lai et al, 2002) 
Oci-Ly1 
Diffuse Large B-cell lymphoma (B-cell, 
EBV-) 
(Tweeddale et al, 1987) 
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2.2 Chemicals, solutions and consumable supplies 
Chemicals, solutions and consumables used in the study are listed in Table 2 and 
Table 3. 
Table 2: Chemicals and solutions 
Chemical or solution Manufacturer 
4-IPBA Sigma-Aldrich, Munich, DE 
Acetic acid Roth, Karlsruhe, DE 
Acrylamide/bisacrylamide 40 % BioRad, Munich, DE 
Ammonium persulphate Sigma-Aldrich, Munich, DE 
Bovine serum albumin (BSA) Serva, Heidelberg, DE 
Bradford solution RotiQuant-Roth, Karlsruhe, DE 
Bromophenol blue Sigma-Aldrich, Munich, DE 
Calcium chloride Merck Millipore, Billerica, US 
Chicken eggs 
Valo BioMedia GmbH, Osterholz-
Scharmbeck, DE 
Collagen (type-) Trevigen, Gaithersburg, US 
Deoxyribonucleoside triphosphates 
(dATP, dCTP, dGTP, dTTP) 
PrimeTech LTD, Minsk, BY 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich, DE 
DMEM Biochrom AG, Berlin, DE 
Eosin Roth, Karlsruhe, DE 
Ethanol (100 %) J.T. Baker, Deventer, NL 
Ethylenediaminetetraacetic acid (EDTA) Riedel-de Haën, Seelze, DE 
ExoQuick-TC Solution 
System Biosciences, Mountain View, 
US 
Formaldehyde Sigma-Aldrich, Munich, DE 
Full Range Rainbow Molecular Weight 
Marker 
GE Healthcare, Munich, DE 
G418 Roche, Basel, CH 
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Glutaraldehyde Roth, Karlsruhe, DE 
Glycerol Roth, Karlsruhe, DE 
Glycine Roth, Karlsruhe, DE 
HEPES Sigma-Aldrich, Munich, DE 
Hot FIREpol DNA polymerase  PrimeTech LTD, Minsk, BY 
Hydrogen peroxide Sigma-Aldrich, Munich, DE 
Isopropanol Sigma-Aldrich, Munich, DE 
Luminol Sigma-Aldrich, Munich, DE 
Magnesium chloride PrimeTech LTD, Minsk, BY 
Matrigel BD Biosciences, Franklin Lakes, US 
Mayer’s alum haematoxylin solution Roth, Karlsruhe, DE 
Methanol 100 % (p.a.) J.T. Baker, Deventer, NL 
Methyl cellulose Sigma-Aldrich, Munich, DE 
Milk powder Roth, Karlsruhe, DE 
MTT reagent Sigma-Aldrich, Munich, DE 
Nonidet P-40 Sigma-Aldrich, Munich, DE 
Osmium tetraoxide Roth, Karlsruhe, DE 
Paraformaldehyde Roth, Karlsruhe, DE 
PBS pH 7.4 (cell culture grade)  PAN-Biotech GmbH, Aidenbach, DE 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Munich, DE 
Phosphatase inhibitor phospho-STOP Roche, Mannheim, DE 
Picric acid Merck Millipore, Billerica, US 
Potassium dihydrogen phosphate 
(KH2PO4) 
Roth, Karlsruhe, DE 
Protamine sulfate Sigma-Aldrich, Munich, DE 
Proteaseinhibitor-mix complete™ Roche, Mannheim, DE 
Puromycin Invivogen, San Diego, US 
ReBlot plus mild  Merck Millipore, Billerica, US 
Roti®-Load 4x loading buffer Roth, Karlsruhe, DE 
RPMI-1640 Lonza, Basel, CH 
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Sodium chloride Merck KGaA, Darmstadt, DE 
Sodium deoxycholate Merck KGaA, Darmstadt, DE 
Sodium dihydrogen phosphate 
(Na2HPO4) 
Roth, Karlsruhe, DE 
Sodium dodecyl sulfate (SDS) Merck KGaA, Darmstadt, DE 
Sodium phosphate dibasic Sigma-Aldrich, Munich, DE 
SYBR Green I Nucleic Acid Gel Stain Roche, Mannheim, DE 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Munich, DE 
Tissue Tek  Poysciences Inc., Warrington, US 
Tris base Sigma-Aldrich, Munich, DE 
TritonX-100 Roth, Karlsruhe, DE 
Trypan blue 0.4 % in PBS Life Technologies, Carlsbad, US 
Trypsin/EDTA (cell culture grade) Biochrom AG, Berlin, DE 
Tween-20 Merck KGaA, Darmstadt, DE 
Water HPLC grade Merck KGaA, Darmstadt, DE 
 
Table 3: Consumables 
Consumable Manufacturer 
ABI PRISM® 384-well clear optical 
reaction plate 
Applied Biosystems, Foster City, US 
ABI PRISM® optical adhesive covers Applied Biosystems, Foster City, US 
Cell culture flasks Sarstedt, Nümbrecht, DE 
Cryo tubes Nunc, Wiesbaden, DE 
Diethylaminoethyl-cellulose Whatman®, International Ltd, UK 
Falcon tubes 15 ml, 50 ml Sarstedt, Nümbrecht, DE 
Filter tips, 10 μl, 100 μl, 200μl, 1000 μl Starlab, Ahrensburg, DE 
Immobilon PVDF membranes  Merck Millipore, Billerica, US 
Membranes for Boyden chamber (8 µm, 
10 µm pores)   
Neuroprobe Inc, Gaithersburg, US 
 
Nitrocellulose membrane Life Technologies, Carlsbad, US 
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Nucleofection cuvettes Lonza, Basel, CH 
Pasteur pipettes Sarstedt, Nümbrecht, DE 
Pipette tips (w/o filters) 100 μl, 1000 μl Sarstedt, Nümbrecht, DE 
Reaction tubes 0.5 ml, 1.5 ml, 2 ml Sarstedt, Nümbrecht, DE 
Serological pipettes 5 ml, 10 ml, 25 ml Sarstedt, Nümbrecht, DE 
Sterling nitrile powder-free examination 
gloves 
Kimberly-Clark, Zaventem, BE 
Tissue culture dish Sarstedt, Nümbrecht, DE 
Tissue culture plates, 6 well, 12 well, 
24 well 
Nunc, Wiesbaden, DE 
μ-Slide chemotaxis3D chamber Ibidi, Martinsried, DE 
2.3 Buffers and Media 
Recipes of buffers and media used for this study are listed in Table 4. 
Table 4: Recipes of buffers and media 
Liquid Receipt/Manufacturer 
2x Hepes-buffered NaCl 
solution (lentivirus 
production) 
0.28 M NaCl 
0.05 M HEPES 
1.5 mM Na2HPO4 
adjust to pH 7.0; sterile-filtered 
Acidic MTT solution 
33 % DMSO 
62 % isopropanol 
5 % formic acid 
Bouin’s solution 
5 % acetic acid 
9 % formaldehyde 
0.9 % picric acid 
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Cell culture medium 
cHL cell lines) 
RPMI-1640 
10 % (v/v) FCS (Biochrom AG, Berlin, DE) 
200 U/ml penicillin + 200 μg/ml streptomycin + 
4 mM L-glutamine (PSG) (Sigma-Aldrich, Munich, DE) 
Cell culture medium 
NHL cell lines) 
RPMI-1640 
10 % (v/v) FCS (Sigma-Aldrich, Munich, DE) 
200 U/ml penicillin + 200 μg/ml streptomycin + 
4 mM L-glutamine (PSG) (Sigma-Aldrich, Munich, DE) 
Cell culture medium 
HUVEC) 
EBM2 medium 
10 % (v/v) FCS plus EGM-2 SingleQuot Kit Suppl. & 
growth factors (all Lonza, Basel, CH) 
Cell culture medium V
cHL pGIPZ cell lines) 
RPMI-1640 
10 % (v/v) FCS (Biochrom AG, Berlin DE) 
200 U/ml penicillin + 200 μg/ml streptomycin + 
4 mM L-glutamine (PSG) (Sigma-Aldrich, Munich, DE) 
2 µg/ml puromycin 
Cell culture medium V 
(mouse fibroblasts; 
L-cells; HEK293T) 
DMEM (Biochrom AG, Berlin, DE) 
10 % (v/v) FCS (Sigma-Aldrich, Munich, DE) 
Cell culture medium V 
(selection medium for 
L-cells) 
DMEM (Biochrom AG, Berlin, DE) 
10 % (v/v) FCS (Sigma-Aldrich, Munich, DE) 
0.4 mg/ml G-418 
Freezing medium 
90 % (v/v) FCS 
10 % (v/v) DMSO 
Karnovsky’s fixative 
0.3 M Soerensen-Buffer 
3 % paraformaldehyde 
3  % glutaraldehyde 
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NP-40 lysis buffer 
50 mM Tris pH 7.4 
150 mM NaCl 
1 mM EDTA 
0.5 % NP-40 
1 x Complete Mini Protease Inhibitor 
1 x PhosStop 
Nuclear Extract Buffer A 
10 mM HEPES pH 7.9 
10 mM KCl 
100 μM EDTA 
100 μM EGTA 
1 mM DTT 
1 x Complete Mini Protease Inhibitor 
1 x PhosStop 
Nuclear Extract Buffer B 
20 mM HEPES pH 7.9 
400 mM KCl 
1 mM EDTA 
1 mM EGTA 
1 mM DTT 
1 x Complete Mini Protease Inhibitor 
1 x PhosStop 
PCR buffer (10x) 
750 mM Tris-HCl pH 8.8 
200 mM Ammonium sulfate 
0.1 % Tween-20 
Running buffer (1x) 
25 mM Tris-Base 
192 mM Glycin 
34.67 mM SDS 
Separation Gel Mix 
31.3 % (v/v) Acrylamide/Bis Solution (40 %) 
332 mM Tris Base, pH 8.9 
3.33 mM EDTA 
Soerensen-Buffer 54.6 mM KH2PO4 
245.4 mM Na2HPO4 






100 mM Tris/HCl pH 8.8 
2.5 mM Luminol 




100 mM Tris/HCl pH 8.8 
10.6 mM H2O2  
Stacking Gel Mix 
15 % (v/v) Acrylamide/Bis Solution (40 %) 
125 mM Tris base pH 6.8 
0.1 % (w/v) SDS 
5 mM EDTA 
SYBRGreenMix 
1 x PCR buffer 
3 mM MgCl2 
1:80.000 SYBRGreen 
0.2 mM dNTP each 
20 U/ml Hot FIREpol DNA polymerase 
0.25 % TritonX-100 
0.5 mM Trehalose in depc water 
TBS (1x) 
20 mM Tris-base 
137 mM Sodium Chloride, pH 7.6 
TBS-T 
1 x TBS 
0.1 % (v/v) Tween-20 
Transfer buffer (1x): 
25 mM Tris-base 
192 mM Glycine 
15 % (v/v) MeOH 
 
2.4 Equipment 
Equipment used for this study is listed in Table 5. 
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Table 5: Equipment 
Instrument Manufacturer 
ABI PRISM 7900HT Fast Real-time 
PCR System 
Thermo Fisher Scientific, Waltham, US 
Accu-jet Brand, Hamburg, DE 
Biofuge Pico, Primo R Heraeus Instruments, Hanau, DE 
Boyden chamber Neuroprobe Inc, Gaithersburg, US 
CAT RM 5 horizontal roller CAT M Zipperer, Staufen, DE 
Centrifuge 5451D Eppendorf, Hamburg, DE 
Consort E734 Power Supply Schütt Labortechnik, Göttingen, DE 
FACS Aria  BD Biosciences, Franklin Lakes, US 
Hera freeze -80°C freezer Heraeus Instruments, Hanau, DE 
IKA KS 260 shaker IKA, Staufen, DE 
IKAMAG RCT magnetic stirrer IKA, Staufen, DE 
Incubator Cytoperm Heraeus Instruments, Hanau, DE 
Incudrive incubator Schütt Labortechnik, Göttingen, DE 
LAS-4000 Image Reader Fujifilm, Düsseldorf, DE 
Leica DM 5000B with camera: DFC290 Leica Microsystems GmbH, Wetzlar, DE 
Microcoolcentrifuge 1-15k Sigma, Munich, DE 
Microflow Laminar Downflow 
Workstation: Telstar Bio-II-A 
Azbil Telstar Technologies, Terrassa, 
ES 
Motic SMZ-161 with Moticam 3.0 
camera (CAM overviews) 
Motic Asia, Hong Kong, CN 
Multifuge 3 L-R Heraeus Instruments, Hanau, DE 
ND-1000 UV/Vis-Spectrophotometer Thermo Fisher Scientific, Waltham, US 
Neubauer Counting Chamber Improved Lo Labor Optik, Friedrichsdorf, DE 
Nucleofector 2b Device Lonza, Basel, CH 
Olympus IX81 with Olympus XM-10 
camera (time-lapse microscopy)  
Olympus, Shinjuka, JP 
Power Pac 300 Power Supply Bio-Rad, Munich, DE 
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Tecan Infinite F50 Reader Tecan Group Ltd., Männedorf, CH 
Thermocycler T3000 Biometra, Göttingen, DE 
Thermomixer Compact Eppendorf, Hamburg, DE 
Vortex Genie 2 Schütt Labortechnik, Göttingen, DE 
Water bath 




Inhibitors used in this study are listed in Table 6. 
Table 6: Inhibitors 
2.6 Recombinant proteins 
The cHL cell lines were stimulated with 100 ng/ml recombinant WNT5A protein 
(R&D Systems, Minneapolis, US) for 24 hours. As chemoattractant for migration 
and invasion assays recombinant human MIP-3β/CCL19 (R&D Systems, 
Minneapolis, US) has been used. 
Inhibitor (target) Manufacturer 
Final 
concentration 
ACHP (IKKα/β) Merck Millipore, Billerica, US 7 µM 
Box5 (WNT5A antagonist) Merck Millipore, Billerica, US 100 µM 
DKK1 (LRP5/6) R&D Systems, Minneapolis, US 100 ng/ml 
DKK2 (LRP5/6) R&D Systems, Minneapolis, US 100 ng/ml 
H1152P (ROCK) Tocris, Bristol, UK 0.5 µM 
IWP-2 (porcupine) StemRD, Burlingame, US 5 µM StemRD, Burlingame, US 5 µ  
PF670462 (CKε/δ) Merck Millipore, Billerica, US 50 nM 
Wnt-C59 (porcupine) Selleck Chemicals, Houston, US 5 µM 
XAV-939 (tankyrases) Merck Millipore, Billerica, US 5 µM 
Y-27632 (ROCK) Merck Millipore, Billerica, US 5 µM 




Plasmids used for virus generation or protein overexpression are listed in Table 7. 
Table 7: Plasmids 




expression vector of V5 
tagged active WNTs 
Addgene, Cambridge, US 
The plasmid kit was a gift 
from Marian Waterman, 
David Virshup and Xi He 
(Najdi et al, 2012; 
MacDonald et al, 2014). 
pCDNA-DVL3K435M-
FLAG 
expression vector of 
mutant K435M DVL3 
variant 
kindly provided by 
Vitezslav Bryja (Bernatík 
et al, 2014) 
pCDNA-DVL3wt-FLAG DVL3 expression vector 
kindly provided by 
Vitezslav Bryja (Bernatík 
et al, 2014) 
pCMV delta R8.2 
packaging plasmid for 
lentivirus production 
Addgene, Cambridge, US 
pGIPZ LEF-1 shRNA 
lentiviral vector containing 
LEF-1sh sequence 




lentiviral vector containing 
non-silencing control 
sequence 
Thermo Fisher Scientific, 
Waltham, US 
pMD.2G    
envelope plasmid for 
lentivirus production 
Addgene, Cambridge, US 
 
2.8 Antibodies 
Antibodies used for immunoblotting are listed in Table 8. 
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Table 8: Antibodies 
Antibody Source Working solution 
goat anti mouse HRP 
polyclonal (sc-2005) 
Santa Cruz, Dallas, US 
1:5000 in 5 % BSA or 5 % 
milk powder in TBS-T 
goat anti rabbit HRP 
polyclonal (sc-2004) 
Santa Cruz, Dallas, US 
1:5000 in 5 % BSA or 5 % 
milk powder in TBS-T 
goat anti rat HRP 
polyclonal (sc-2006) 
Santa Cruz, Dallas, US 
1:5000 in 5 % BSA or 5 % 
milk powder in TBS-T 
mouse anti FLAG (8146) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
mouse anti GAPDH 
(ab8245) 
abcam, Cambridge, UK 
1:20000 in 5 % BSA in 
TBS-T 
mouse anti HSP90 (sc-
13119 ) 
Santa Cruz, Dallas, US 
1:1000 in 5 % BSA in 
TBS-T 




1:500 in TBS-T 
mouse anti TCF4 
Merck Millipore, Billerica, 
US 
1:1000 in 5 % milk 
powder in TBS-T 
mouse anti Tubulin 
(05-829) 
Merck Millipore, Billerica, 
US 
1:5000 in 5 % BSA in 
TBS-T 
mouse anti β-catenin 
(610153) 
BD Biosciences, Franklin 
Lakes, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti DVL1 
(ab106844) 
abcam, Cambridge, UK 
1 µg/ml in 5 % BSA in 
TBS-T 
rabbit anti DVL2 (3216) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % milk 
powder in TBS-T 
rabbit anti DVL3 (3218) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti FZD5 (5266) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
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rabbit anti HDAC (2062) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti IKK1 (2682) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti LEF-1 (2286) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti p38 (9212) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti STAT3 (9132) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 
rabbit anti TCF3 
Merck Millipore, Billerica, 
US 
1:1000 in 5 % milk 
powder in TBS-T 
rabbit anti V5 (13202S) 
Cell Signalling 
Technology, Danvers, US 
1:1000 in 5 % BSA in 
TBS-T 




1:1000 in 5 % milk 
powder in TBS-T 
2.9 Oligonucleotides and siRNAs 
Primers used for quantitative real-time PCR (qRT) are listed in Table 9 and 
siRNAs used for transient gene knockdowns are listed in Table 10. Primers as well 
as random hexamer primers have been generated by IBA GmbH (Göttingen, DE). 
Table 9: Oligonucleotides 
Oligonucleotides Sequence 
ABL 
fwd: 5’ AGC CTG GCC TAC AAC AAG TTC TC 3’ 
rev: 5’ GAC ATG CCA TAG GTA GCA ATT TCC 3’ 
FZD5 
fwd: 5’ GTC ACA CCC GCT CTA CAA CA 3’ 
rev: 5’ GGA CGT GGA GAT GAA GCA CA 3’ 
LEF-1 
fwd: 5’ TAA TGC ACG TGA AGC CTC AGC 3’ 
rev: 5’ TTA ATG TGA GGT CTT TTT GGC TCC 3’ 




fwd: 5’ AAC CTG AAG ACA CAA GCA GAG TCC 3’ 
rev: 5’ AAC CTG AAG ACA CAA GCA GAG TCC 3’ 
TCF7L1 
fwd: 5’ CGC GGG ACT ATT TCG CCG AAG 3’ 
rev: 5’ TGG AGA GGT ACG GGC TGC TCA G 3’ 
TCF7L2 
fwd: 5’ CAT CAC CGG CAC ACA TTG TC 3’ 
rev: 5’ GTT CAT TGC TGT ACG TGA TAA GAG GC 3’ 
WNT3A 
fwd: 5’ CAG GAA CTA CGT GGA GAT CAT GC 3’ 
rev: 5’ TCC TGG ATG CCA ATC TTG ATG 3’ 
WNT5A 
fwd: 5’ AGG GCT CCT ACG AGA GTG CT 3’ 
rev: 5’ GAC ACC CCA TGG CAC TTG 3’ 
WNT10A 
fwd: 5’ CCA GGT CAG CAC CCA ATG ACA TT 3’ 
rev: 5’ CCT GGC AAT GTT AGG CAC ACT GTG 3’ 
WNT10B 
fwd: 5’ CTG TGT GAT GAG TGC AAG GTT ACA G 3’ 
rev: 5’ CCC TCA CTT ACA CAC ATT CAC CC 3’ 
WNT16 
fwd: 5’ GGC TAC GAG CTG AGC AGC G 3’ 
rev: 5’ CAT GAC CTG GTC ACA GAA TGC A 3’ 
 
Table 10: siRNA 
siRNA Manufacturer 
DVL3si (s675) Life Technologies, Carlsbad, US 
FZD5si (pool of HSS111796, 
HSS111798, HSS187902) 
Life Technologies, Carlsbad, US 
LEF-1si (pool of ID108840, IDs27618, 
IDs27617, IDs27616) 
Life Technologies, Carlsbad, US 
MAPK14si (SMARTpool: ON-
TARGETplus MAPK14 siRNA, L-
003512-00) 
GE Healthcare Dharmacon, Lafayette, 
US 
scrambled si control (scr, AM4611) Life Technologies, Carlsbad, US 




TARGETplus STAT3 siRNA, 
L-003544-00) 
GE Healthcare Dharmacon, Lafayette, 
US 
β-catenin si (pool of ID J-003482-09, ID 
J-003482-12) 
GE Healthcare Dharmacon, Lafayette, 
US 
2.10 Ready to Use Reaction Systems 
Ready to use reaction systems and kits used in this study are listed in Table 11. 
Table 11: Ready to use reaction systems 
Ready to use reaction system Manufacturer 
Cell Line Nucleofector® Kit L (for L428)/ 
Kit T (for KM-H2) 
Lonza, Basel, CH 
Nucleo Spin RNA II Machery+Nagel, Düren, DE 
RHOA Pull-down Activation Assay 
Biochem Kit 
Cytoskeleton Inc., Denver, US 
Superscript II™ RT Kit Invitrogen, Karlsruhe, DE 
2.11 Software 
Software used for this study is listed in Table 12. 
Table 12: Software 
Software Developer 
ABI 7900HT Sequence Detection 
Systems Ver. 2.4 
Thermo Fisher Scientific, Waltham, US 
Adobe Illustrator CS6 Ver 16.0.3 Adobe Systems Inc. San José, US 
Adobe Photoshop CS2 Ver 9.0 Adobe Systems Inc. San José, US 
Chemotaxis and Migration Tool Ibidi, Martinsried, DE 
GraphPad Prism 6.04 GraphPad Software Inc., La Jolla, US 
ImageJ software 1.45s National Institutes of Health, Bethesda, US 
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Leica Application Suite Ver 3.8.0 Leica Microsystems GmbH, Wetzlar, DE 
Magellan for F50 7.0 Tecan Group Ltd., Männedorf, CH 
Mendeley Desktop Ver 1.15.2 Mendeley Ltd, London, UK  
Microsoft Office (Word, Excel, 
PowerPoint) 
Microsoft Corporation, Redmont, US 
ND-1000 V3.8.1 Thermo Fisher Scientific, Waltham, US 
Oncomine web platform Life Technologies, Carlsbad, US 
RQ Manager Ver. 1.2.1 Thermo Fisher Scientific, Waltham, US 
Servier Medical Art (licensed under a 
Creative Commons Attribution 3.0 
Unported License) 
Les Laboratoires Servier, Neuilly-sur-
Seine, FR 
Xcellence Imaging Software for Life 
Science Microscopy 
Olympus, Shinjuka, JP 
2.12 Cell Biology 
2.12.1 Cell culture 
The cHL cell lines L428, KM-H2 and L1236 were cultured in cell culture 
medium while the BL cell lines BL-2 and BL-30, the MCL cell lines JeKo-1 and 
Mino and the DLBCL cell lines OciLy1, Carnaval and Karpas-422 were cultured in 
cell culture medium . All cells were maintained at 37°C in 5 % CO2. The cHL, 
MCL and DLBCL cells were seeded at a density of 5 x 105 cells/ml the day before 
the experiment while BL cell lines were seeded at a density of 3 x 105 cells/ml. For 
cell number measurement cells were mixed in an equal ratio with 0.4 % Trypan 
blue and counted using the Neubauer counting chamber.  
Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in cell culture 
medium . For the experiments HUVEC cells with a confluence of 80-90 % and 
from passage two till six have been used. 
Material and Methods    
35 
 
Mouse fibroblasts (WNT3A/WNT5A) have been cultured in cell culture 
medium Vand wildtype L-cells in cell culture medium V. Approximately every 
three days L-cells were subcultivated (ratio: 1:4 to 1:10). 
HEK293T cells have been cultured in cell culture medium V. Approximately 
2-3 x 106 cells/80 cm2 have been seeded and subcultivated (ratio: 1:4 to 1:5) every 
three days. 
All cell lines have been tested regularly for mycoplasma contamination. Cells were 
no longer than four weeks continuously cultivated. For cell freezing 3 x 106 till 
5 x 106 cells were centrifuged at 100 x g/7 min and resuspended in 1 ml freezing 
medium. For the freezing process cryo boxes which contain isopropanol were 
used to ensure a constant cooling of approximately 1°C/min. Cryo boxes were 
stored immediately at -80°C for 24 hours before they were transferred to -150°C 
for long-term storage. For thawing cells were washed with their corresponding 
culture medium, counted and seeded in new culture medium (cHLs, DLBCLs, 
MCLs: 5 x 105 cells/ml; BLs: 3 x 105 cells/ml). 
2.12.2 RNA-interference-mediated gene knockdown and gene 
overexpression by nucleofection 
Small-interfering RNA (siRNA) against the indicated target genes or nonsense 
controls (ns ctr) were transfected into the cells using Cell Line Nucleofector Kit 
(L428: Kit L; KM-H2: Kit T) and the Nucleofector 2b Device (2 μg siRNA/plasmid 
per two million cells) according to the manufacturer’s instructions (programme 
X001 for L428 and T-001 for KM-H2). After the nucleofection process cells were 
incubated in pre-warmed RPMI 1640 supplemented with 10 % (v/v) FCS, 200 U/ml 
penicillin, 200 μg/ml streptomycin, 1 mM sodium pyruvate and 10 mM Hepes for 
48 hours at 37°C in 5 % CO2. Knockdown quality was verified with qRT-PCR and 
immunoblotting. 
For WNT overexpression pCDNA3.2 plasmids containing corresponding V5-
tagged WNT ligands were used from the WNT Open Source Kit. pCDNA-DVL3wt-
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FLAG and pCDNA-DVL3K435M-FLAG plasmids have been described recently 
(Bernatík et al, 2014). 
2.12.3 Preparation of conditioned medium (CM) 
For the preparation of conditioned HL medium L428, KM-H2 or L1236 have been 
seeded at a density of 5 x 105 cells/ml and incubated in cell culture medium  for 
two days. Cell supernatant was centrifuged at 300 x g for 10 min at 4°C, sterile 
filtered and stored at 4°C for a maximum of two weeks. 
For the preparation of conditioned L-cell medium mouse fibroblasts (L-cell 
wildtype/WNT3A/WNT5A) have been seeded at a density of 8000 cells/cm2 and 
incubated in cell culture medium V for four days. Cell supernatant was centrifuged 
at 300 x g for 10 min at 4°C and stored at 4°C. New cell culture medium V was 
added to the L-cells for three more days. The second supernatant was added to 
the first one after centrifugation in an equal ratio. Finally the conditioned medium 
was sterile filtered and stored at 4°C for a maximum of two months. 
2.12.4 Isolation and preparation of extracellular vesicles (EVs) 
EVs have been isolated using ExoQuick-TC Solution following the manufacturer’s 
instructions. Shortly, ExoQuick-TC Precipitation Solution has been added to the 
cell supernatant, mixed and incubated at 4°C overnight. The mixture has been 
centrifuged at 1500 x g twice and the dry pellet has been resuspended in PBS for 
stimulation assays or NP-40 lysis buffer for Western Blot analysis. 
As another possibility ultracentrifugation has been used for EV preparation as 
described recently (Menck et al, 2013). 
2.12.5 Inhibitor treatment 
For porcupine inhibition the chemical compounds Wnt-C59 or IWP-2 have been 
added to the cell culture medium at a final concentration of 5 μM in DMSO for 
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72 hours. Each 24 hours the inhibitor and the corresponding DMSO control were 
renewed. 
For inhibition of the canonical WNT pathway the CK1 inhibitor PF670462, the 
tankyrases inhibitor XAV939 or DKK1 and DKK2 have been added to the cell 
culture medium at a final concentration of 50 nM (PF670462) or 5 μM (XAV939) or 
100 ng/ml (DKK1, DKK2) in DMSO (PF670462, XAV939), PBS (DKK2) or PBS 
with 0.1 % BSA (DKK1) respectively for 24 hours. 
For inhibition of ROCK the inhibitors Y-27632 or H1152P have been added to the 
cell culture medium at a final concentration of 5 μM (Y-27632) or 0.5 μM (H1152P) 
in DMSO respectively for 24 hours. 
For IKK2 inhibition ACHP has been applied at a final concentration of 7 μM in 
DMSO for 24 hours. 
For antagonizing WNT5A Box5 has been applied at a final concentration of 
100 μM in DMSO for 24 hours. 
2.12.6 WNT stimulation 
Before stimulation cHL cells were serum-starved and treated with the Porcupine 
inhibitor Wnt-C59 (5 μM) for 48 hours. cHL cell lines were either stimulated with 
100 ng/ml recombinant WNT5A ligand or with corresponding WNT ligand 
containing L-cell conditioned medium for the indicated times. 
For migration and chorio-allantoic membrane (CAM) experiments cHL cells have 
not been serum-starved before. 
2.12.7 Lentivirus production 
For lentivirus production 5 x 106 HEK293T cells have been seeded per 10 cm2 cell 
culture dish and grown to 80 % confluence. Two hours prior to the experiment 
HEK293T medium has been renewed without disturbing cell confluence. 
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Expression vector (pGIPZ LEF1 shRNA or pGIPZ non-silencing control), 
packaging plasmid (pCMV delta R8.2) and envelope plasmid (pMD.2G) have been 
mixed in the ratio 3:2:1. Calcium chloride solution has been added to a final 
concentration of 0.5 M. While the calcium chloride-plasmid mixture has been 
mixed thoroughly the same volume of 2x Hepes-buffered NaCl solution has been 
added drop by drop. The final mixtures have been incubated for 3 min at room 
temperature, mixed again and then carefully been added drop by drop to the 
HEK293T cells. The next day cell supernatant has been removed and 5 ml of cell 
culture medium V have been added carefully to each dish. HEK293T cells have 
been incubated for 24 hours at 37°C in 5 % CO2 before the first virus harvest has 
been performed. For that purpose HEK293T cell supernatant has been taken off 
and stored at 4°C and HEK293T cells have been covered again with 5 ml of cell 
culture medium V per dish. After another day of incubation the second 
supernatants have been taken off and mixed with the respective first supernatants. 
The resulting virus solutions have been centrifuged at 2000 x g for 10 min at 4°C. 
To remove residual cell debris supernatants have been transferred to new tubes 
and sterile filtered. Virus solution has either been used immediately for transfection 
controls or cHL cell transduction or stored at -80°C. 
2.12.8 Lentiviral transduction and selection of pGIPZ cHL cells 
Cell concentration of L428 and KM-H2 cells has been adjusted to 1 x 106 cells/ml 
in RPMI1640 medium supplemented with 20 % (v/v) FCS, 200 U/ml penicillin, 
200 μg/ml streptomycin, 4 mM L-glutamine and 10 µg/ml protamine sulfate. Virus 
solution and cell suspension have been mixed in an equal ratio and centrifuged at 
300 x g for 90 min at 37°C. The cHL cell-virus suspensions have been incubated 
for 48 hours. Since the pGIPZ plasmid contains an additional puromycin 
resistance selection process has been started by adding puromycin to a final 
concentration of 2 µg/ml to the cells on the second day after transduction. To 
control the selection process L428 and KM-H2 cells without virus addition also 
have been treated with puromycin but those cells died within two days. Lentiviral 
transduced L428 and KM-H2 cells have been grown in cell culture medium V and 
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frozen for long-term storage as described in 2.12.1. LEF-1 knockdown has been 
regularly confirmed using qRT-PCR and immunoblot techniques (2.13.2 and 
2.14.3). 
2.12.9 Migration and invasion assay 
The migratory potential of the cHL and NHL cells was assessed using the Boyden 
chamber with defined porous membranes (for cHLs, MCLs: 8 μm, for BLs, 
DLBCLs: 10 μm). In short, the lower chamber was filled with RPMI 1640 alone 
(undirected migration) and RPMI 1640 supplemented with 10 % (v/v) FCS and 
50 nM MIP-3β/CCL19, the membrane was applied free from air bubbles and the 
upper chamber was filled with 50.000 untreated, inhibitor-treated or nucleofected 
cells per well in RPMI 1640 medium. After 6 hours of migration time (cHLs and 
MCLs) or 16 hours (BLs, DLBCLs) cells from the upper chamber were removed 
and the migrated cells in the lower chamber were counted. Basal cell migration 
towards RPMI 1640 medium only was set one. For stimulation experiments the 
lower chamber was filled with RPMI 1640 supplemented with 1 % (v/v) FCS. Six 
wells per condition were used in every experiment. 
For invasion assays 8 μm porous membranes were coated with 1 mg/ml 
type-collagen and invasion was measured after 16 hours as described above. 
2.12.10 Time-lapse microscopy of cell chemotaxis 
For monitoring real-time cell movements cHL cells (3 x 106 cells/ml) were added 
into the μ-Slide chemotaxis3D chamber in 1.5 mg/ml type--collagen. Chemotaxis 
towards 10 % (v/v) FCS and 50 nM MIP-3β/CCL19 was documented for 6 hours 
with one photo per 5 min by time-lapse microscopy. For trajectory analysis of 50 
cells per condition ImageJ 1.45s (plugin: manual tracking) and the Ibidi software 
“Chemotaxis and Migration Tool” were used. 
Cell track analysis using shape fingerprint descriptors has been performed by 
Manuel M. Nietert (Department of Medical Statistics, University Medical Centre of 
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the Georg-August University of Göttingen, Göttingen). A detailed description of the 
method can be found in the Appendix.  
2.12.11 Adhesion assay 
Adhesion assays have been performed as described recently (Zepeda-Moreno et 
al, 2014). Shortly, 96 well plates have been coated with 1 mg/ml type-collagen or 
seeded with HUVEC cells overnight. Inhibitor-treated or transfected cHL cells have 
been added to the wells (75.000 cells/well/320 µl) in quadruplicates and incubated 
for 1 hour at 37°C in 5 % CO2. For discrimination between adherent and non-
adherent cells the plate has been turned up-side down and incubated for two more 
hours at 37°C in 5 % CO2. While holding the plate still up-side down the 
supernatant with the non-adherent cells has been carefully transferred to a second 
plate. Additionally, five different known numbers of cells have been added for each 
condition in duplicates to this second plate for the standard curve calculation. For 
cell number quantification MTT solution has been added to a final concentration of 
0.5 mg/ml and incubated with the non-adherent cells and the cells for the standard 
curve for 3 hours at 37°C in 5 % CO2. Optical density has been determined at 
560 nm using the Tecan Infinite F50 Reader. Standard curves have been 
calculated for each condition and the amount of adherent cells has been 
presented in percentage of the total number. 
2.12.12 MTT assay 
For cell viability tests cell lines have been pretreated with inhibitor as described 
above and subsequently seeded into a 96 well plate. After the addition of 
0.5 mg/ml MTT reagent, cells have been incubated for four hours at 37°C in 
5 % CO2 followed by centrifugation and resuspension of the cell pellet in the acidic 
MTT solution. Optical density has been determined at 560 nm using Tecan Infinite 
F50 Reader. 
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2.12.13 RHOA activity assay 
RHOA Activity has been measured with the RHOA Pull-down Activation Assay 
Biochem Kit following the manufacturer’s instructions. Shortly, stimulated cells 
have been lysed and snap-frozen in liquid nitrogen. For positive and negative 
controls lysate was incubated with GDP or the GTP analogue GTPγS before the 
pull-down started. Equal lysate amounts were incubated with 50 µg rhotekin-RBD 
beads at 4°C for one hour. Beads were washed, resuspended in Roti-Load loading 
dye and boiled at 95°C for 5 min. The following SDS page and immunoblotting is 
described in 2.13.2 SDS page and Western Blot. 
2.12.14 HUVEC spheroid assay 
For spheroid generation HUVEC cells have been mixed with 1.2 % methylcellulose 
in cell culture medium  and incubated in 96 well plates for 24 hours. Roundly 
formed spheroids have been harvested and seeded with one part matrigel and two 
parts KM-H2 conditioned medium in 96 well plates for 48 hours. At least 
12 spheroids have been seeded per condition. For positive controls spheroids 
have been seeded with cell culture medium . Photos of each spheroid have 
been taken after 48 hours and sprouting frequency has been calculated as relation 
between sprouted spheroids and totally seeded spheroids per condition. From 
every sprouted spheroid total sprout length and tip number have been calculated 
using ImageJ software 1.45s. 
2.12.15 HUVEC tube formation assay 
HUVEC cells have been seeded as single cell suspension in matrigel mixed with 
two parts of the particular cHL conditioned medium and one part cell culture 
medium in 96 well plates. Four wells per condition have been used. After 
16 hours tubes have been formed throughout the well. Three photos per well have 
been taken and total tube lengths have been measured using ImageJ 
software 1.45s 
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2.12.16 Chick chorio-allantoic membrane (CAM) assay 
The CAM assay has been performed by Frederike von Bonin including sawing the 
egg shells, cell inoculation, the tumour harvest, fixation and eventually H&E 
staining. The prior cell treatment and the later evaluation including development of 
the haemorrhage score, assessment of the results, microscoping H&E stained 
slices and statistics have been performed by me. 
In short, chicken eggs have been bred and regularly turned around for 4 days at 
37.8°C and 80 % air humidity. For the in ovo assay a 0.75 cm² window has been 
sawed into the egg shell at the fourth day of chicken embryo development. At day 
eleven of chicken embryo development 2 x 106 pretreated L428 cells embedded in 
20 μl Matrigel have been added on the CAM. After 4 days of incubation on the 
CAM, tumours have been cut out, evaluated, photographed and fixed either in 
Bouin’s solution or 4 % paraformaldehyde solution with a subsequent ascending 
series of saccharose. For histological analysis tumours were embedded in paraffin 
or Tissue Tek and cut. Tumour areas have been measured using the light 
microscopy photos and ImageJ software 1.45s.  
2.12.16.1 Haematoxylin and eosin (H&E) staining  
Tumour sections have been fixed in 100 % methanol for 5 min. After 2 min of 
washing with distilled water, sections were incubated in Mayer’s alum 
haematoxylin solution for 2 min, rinsed in running tap water, incubated in eosin for 
7 min and again washed with distilled water. For dehydration an ascending ethanol 
series with a final incubation in xylol has been used. Dried and mounted sections 
have been analysed using light microscopy (Leica DM 5000B, camera: DFC290). 
2.12.16.2 Semi-thin and ultra-thin sections 
Semi-thin and ultra-thin sections have been performed in the Department of 
Anatomy and Cell Biology of the University Medical Centre of the Georg-August 
University of Göttingen by the working group of Prof. Dr. Jörg Wilting. 
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Shortly, tumours have been fixed in Karnovsky’s fixative, post-fixed in osmium 
tetroxide solution and embedded in Epon resin according to standard techniques. 
Semi-thin sections of 750 nm were stained with Richardson solution and studied 
with a light microscope. For transmission electron microscopy ultra-thin sections of 
70 nm were contrasted with lead citrate and uranyl acetate. 
2.12.16.3 Micro-CT scans of CAM tumours 
Micro-CT scans of CAM tumours have been performed by Christian Dullin 
(Institute of Diagnostic and Interventional Radiology; University Medical Centre of 
the Georg-August University of Göttingen, Göttingen). 
In short, CT scans of the PTA stained and agarose gel embedded samples have 
been performed using the GE eXplore Locus SP specimen CT (TriVoil, USA) 
(Verdelis et al, 2011). The system was operated with the following parameters: 
tube voltage 70 kVp, tube current 50 mA, 270° rotation with 667 projection images, 
exposure time per projection 1600 ms, detector binning 2 x 2 resulting in a pixel 
size of 14 μm. In order to increase the signal-to-noise ratio every projection data 
has been acquired twice and averaged. 
2.12.16.4 Scoring hemorrhages in CAM tumours 
The haemorrhage score is based on three criteria: appearance of hemorrhages, 
intensity of hemorrhages and relative area covered by hemorrhages. In each 
criterion zero to three points can be given leading to a maximum of nine points per 
tumour. Examples for each criterion as well as tumour examples for the total 
points are shown in Table 13 and Figure 3. For the evaluation process light 
microscopy pictures of each tumour have been blinded and then evaluated by 
another group member who was not involved in the experiments. 
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Table 13: Hemorrhage score for CAM tumours 
 




Figure 3: Examples of CAM tumours with their respective hemorrhage score. 
2.13 Protein biochemistry 
2.13.1 Whole cell lysates and cell fractionation 
Cells were harvested, centrifuged at 300 x g/5 min/4°C and washed once with 
PBS. 
For whole cell lysates cell pellets of 1 x 106 to 2 x 106 cells have been resuspended 
in 50 µl or 100 µl NP-40 lysis buffer respectively and incubated on ice for 30 min. 
Subsequently, residual cell debris was lost by centrifuging cell suspensions at 
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14.000 x g/15 min/4°C. Supernatants were transferred to new reaction tubes and 
total protein amount was measured using the RotiQuant assay and the Tecan 
Infinite F50 Reader.     
Cell fractionation has been performed as described by Schreiber et al. (Schreiber 
et al, 1989). In short, cell pellets of 1 x 106 to 2 x 106 cells were resuspended in 
400 µl Nuclear Extract Buffer A and incubated on ice for 15 min. Afterwards 25 µl 
10 % NP-40 solution was added to each tube, mixed thoroughly and centrifuged at 
13.000 x g/5 min/4°C. The supernatant containing the cytosolic fraction was 
transferred to a new tube and the pellets were resuspended in each 50 µl Nuclear 
Extract Buffer B and shaken thoroughly for 25 min at 4°C. After centrifugation at 
13.000 x g/5 min/4°C the supernatant containing the nuclear fraction was 
transferred to a new tube and protein amount of both fractions was measured 
using the RotiQuant assay and the Tecan Infinite F50 Reader. 
2.13.2 SDS page and Western Blot 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used for size-fractionation of the proteins (Laemmli, 1970). Polyacrylamide gels 
were composed of a 5 % stacking gel and a 7.5 % to 15 % ranging separation gel 
(DVL: 7.5%; RHOA: 15 %; cell fractions and knockdown controls: 10%).  For SDS 
page 15 µg to 20 µg of protein was mixed with 4x RotiLoad loading dye, 
denaturized at 95°C for 5 min and loaded onto the gel. Additionally, Rainbow Full-
range marker was used to determine protein sizes. The gel was run at 20 mA for 
approximately one hour. Then the stacking gel was separated from the separation 
gel and the separation gel, whatman papers and the methanol-activated PVDF 
membrane were equilibrated in transfer buffer. For the transfer the BioRad Tank 
Blot System was used with the following arrangement: Cathode (-); 2 whatman 
papers; polyacrylamide gel; PVDF membrane; 2 whatman papers; Anode (+). The 
transfer was conducted at 100 V for 1 hour at 4°C. Blots were air-dried, rehydrated 
in TBS-T buffer and incubated in blocking buffer (5 % BSA or milk powder, 0.1 % 
Tween in tris-buffered saline) at room temperature for one hour and afterwards 
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incubated with primary antibody in the respective blocking buffer overnight at 4°C. 
After washing blots were incubated with the respective peroxidase-coupled 
secondary antibody for 1 hour at room temperature. Enhanced chemi-
luminescence detection was used to visualize the immune reaction. Therefore, the 
membrane was incubated with chemiluminescence solution 1 and 2 in equal 
amounts for 1 min and afterwards proteins were detected using 
chemiluminescence camera LAS-4000 Image Reader. For reprobing with another 
antibody blots were incubated in Reblot Mild Plus Buffer at room temperature for 
15 min. 
For WNT5A immunoblotting lysates have not been boiled for SDS page but 
transferred semi-dry onto a nitrocellulose membrane. 
2.13.3 Enzyme-linked immunosorbent assay (ELISA) of VEGFA 
To estimate the VEGFA level in the supernatant of cHL cells Human VEGF 
Quantikine ELISA Kit has been used. VEGFA ELISA has been performed with the 
indicated CMs of WNT5A-stimulated or siRNA transfected L428 and KM-H2 cells 
according to the manufacturer’s instructions. The absorption of the samples has 
been detected at a wavelength of 450 nm (wavelength correction: 540 nm) using 
the Tecan Infinite F50 microplate Reader. 
2.14 Molecular Biology 
2.14.1 mRNA isolation 
Total RNA of cell pellets was isolated using the NucleoSpin RNA Kit according to 
the manufacturer’s instructions. RNA was eluted in 40 µl RNAse free water and 
the corresponding concentration has been determined using the NanoDrop. 
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2.14.2 Reverse transcription 
The Superscript II first-strand synthesis kit and random hexamer primers have 
been used for the reverse transcription of mRNA to cDNA. For the cDNA synthesis 
in each tube 1 µg to 2 µg mRNA have been mixed with RNAse free water to a final 
volume of 10 µl and 2 µl random hexamer primers (100 µM) have been added. 
The mix has been incubated at 70°C for 10 min in a thermocycler. Subsequently, 
the tubes have been cooled on ice, 8 µl master mix have been added to each tube 
and the complete mixtures have been incubated in a thermocycler with the 
programme shown in Table 14. 
Table 14: Master mix and thermocycler programme for the reverse transcription 
Master mix Thermocycler programme 
4 μl 5x First Strand Buffer 42°C 60 min 
2 μl DTT (0.1 M) 65°C 10 min 
1 μl dNTPs (10 mM each) 4°C  ∞ 
1 μl SuperScript RT II  
2.14.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
For relative transcript quantification the fluorescent DNA binding dye SYBR Green 
has been applied. If SYBR Green binds double-stranded DNA, this complex of 
DNA and the SYBR Green dye will absorb blue light (λmax = 488 nm) and emit 
green light (λmax = 522 nm). Therefore, the increasing fluorescence is used to 
quantify the amount of transcripts over the PCR cycles which corresponds to the 
number of PCR cycles with an exponential increase of fluorescence (cycle 
threshold = Ct-value). For the PCR reaction and the simultaneous fluorescence 
detection the ABI PRISM 7900HT sequence detection system and corresponding 
384 well clear optical plates and SYBR Green mix (Table 4) was used. For each 
reaction 5.6 µl SYBR Green mix, 0.3 pmol/μl of each primer and cDNA which 
correlates to 10 ng mRNA has been mixed in a final volume of 10 µl. Each 
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analysis has been performed in triplets. The corresponding qRT-PCR programme 
is shown in Table 15. 
Table 15: qRT-PCR programme 
qRT-PCR step  











Pause 4°C/ ∞ 
Gene expression was evaluated relative to ABL using the SDS 2.4 and the RQ 
Manager 1.2.1 software. Target gene transcript abundance was calculated using 
the ΔCT method. Therefore, the actual Ct-values of genes of interest have been 
normalized to the Ct-values of ABL: 
∆𝐶𝑇 = 𝐶𝑇𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 − 𝐶𝑇 𝐴𝐵𝐿 
2.15 NMR spectroscopy for the quantification of intracellular 
metabolites 
NMR spectroscopy analysis of L428 and KM-H2 pGIPZ cells has been performed 
by our cooperation partners from the Masaryk University (Brno; CZ). Michaela 
Krafčíková and Lukáš Trantírek performed NMR analysis and Petra Ovesná the 
corresponding cluster analysis. 
Sample preparation: Acetonitrile extraction (Dietmair et al, 2010) was employed to 
quench cell metabolism and to quantitatively extract low molecular weight 
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compounds from HL cell lines. Acetonitrile fraction was subjected to overnight 
lyophilisation. Dried extracts were resuspended in 550 µl of D2O containing 
0.005 % sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TSP) as both chemical 
shift reference and internal standard for metabolite quantification.  
NMR spectroscopy: Information on concentration of metabolites in individual 
samples was derived from volumes of corresponding signals in 1D 1H NMR 
spectrum. Assignment of signals in NMR spectra of individual samples to 
particular metabolite was achieved via comparison of a sample spectrum with 
spectra of pure metabolites. The 1D 1H spectra were measured at 700 MHz using 
a Bruker Avance III NMR spectrometer equipped with a triple resonance room 
temperature probe using the WATERGATE pulse sequence (Piotto et al, 1992), 
including 1 ms rectangular selective pulses to suppress the residual signal of 
water. All spectra were acquired at 20°C and processed using TopSpin 3.2 
(Bruker, USA). To compare the metabolite concentration profiles among various 
samples the signal intensities in individual samples were normalized to total 
protein concentration. 
2.16 Microarray data analyses 
Analysis of available microarray mRNA expression data was conducted using the 
Oncomine web platform (Rhodes et al, 2004). The Steidl Lymphoma, Brune 
Lymphoma and Basso Lymphoma datasets have been used (Steidl et al, 2010a; 
Brune et al, 2008; Basso et al, 2005). In the Steidl study 130 HL samples were 
analysed using Human Genome U133 Plus 2.0 Array (19 574 genes, 54 675 
reporters). In the Brune study 42 malignant lymphoma samples and 25 normal 
B-cell samples of various types were analysed using as well the Human Genome 
U133 Plus 2.0 Array. In the Basso study 336 B-cell samples (normal, tumour, cell 
line, and cell line perturbation samples) were analysed using the Affymetrix 
U95Av2 Array (8,603 genes, 12,651 reporters). Data were analysed using 
GraphPad Prism 6.04 and with the friendly support of Pavlína Janovská (Faculty of 
Science, Institute of Experimental Biology, Masaryk University, Brno, CZ). 




Results are shown as mean or as mean ± standard deviation (mean ± SD) of the 
indicated number of samples. The statistical significance of the values was 
determined using the Student's t-test. If applicable group results were compared 
using the ANOVA-method (One-way or Two-way Analysis of Variance) with a 
subsequent Bonferroni’s post-hoc test to correct for multiple comparisons as 
indicated. Normal distribution and homogeneity of variance has been tested using 
the Kolmogorov–Smirnov Test and the F-test. For nonparametric group results 
Kruskal-Wallis test with Dunn’s post-hoc test has been performed. Significance 
levels are indicated as *=p<0.05, **=p<0.01, ***=p<0.001. All statistical analyses 
and plots were done with GraphPad Prism 6.04. 
 
 




The aim of this thesis was the analysis of the cHL cell motility and the interplay 
with endothelial cells regarding WNT signalling.  
At first, the general migration rates of cHL cell lines in comparison to NHL cell lines 
and their particular characteristics were investigated. In this context the impact of 
WNT signalling on in vitro cHL cell migration and in vivo lymphoma engraftment 
were analysed using porcupine inhibitors. The WNT5A-mediated non-canonical 
WNT signalling on cHL cell motility was analysed in more detail. The WNT5A 
signalling cascade was dissected regarding the involved FZD receptor, DVL 
adaptor protein and the small GTPase protein RHOA. In addition, the activation 
status and impact of canonical WNT signalling was investigated. Therefore, 
inhibitors of canonical pathway members were applied and knockdowns of LEF-1 
and β-catenin were performed for migration and invasion assays. Most of these 
data are to be published in (Linke et al, 2016a, 2016b).  
Finally, the last part focuses on the interplay with endothelial cells using 
angiogenesis assays. Therefore, the supernatant of cHL cells were used to 
evaluate the influence of cHL cells on endothelial cells regarding sprouting, tube 
formation and in vivo lymphoma engraftment. Most of these data are also to be 
published in (Linke et al, 2016a, 2016b). 
3.1 cHL cell lines migrate with high rates and depend on 
autocrine WNTs 
At first, the migration rates of different lymphoma entities were compared in 
Boyden chamber assays. Since the high migration potential of CLL and MCL cells 
was shown previously (Xargay-Torrent et al, 2013; Kaucká et al, 2013), the 
question emerged how effective cHL cells migrate compared to CLL and MCL 
cells. Moreover, so far there is no quantitative comparison for BL and DLBCL cells 
available. Therefore, NHL cell lines including MCL cell lines related to small-cell B-
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cell lymphomas such as CLL, as well as BL and DLBCL cell lines belonging to 
initially localized lymphoma were tested in Boyden chamber assays. Figure 4 
shows the results of the migration experiments performed with cHL and MCL cells 
using membranes with 8 µm pores for 6 hours. For BL and DLBCL cells the 
membrane pore size as well as the migration time had to be extended to 10 µm 
pore size and 16 hours migration time to yield evaluable migration rates. The cHL 
cell lines L428, KM-H2 and L1236 showed the highest migration rates with at least 
12 to 20 fold enhanced migration towards the chemoattractant compared to pure 
RPMI medium. Interestingly, MCLs migrated efficiently as expected but with 
approximately almost half the rates compared to cHL cells. In contrast, only little 
enhanced migration rates towards the chemoattractant were detected for BL and 
DLBCL cells despite the simplified migration conditions. Consequently, these 
remarkable migration rates of cHL cells prompted us to investigate the cHL cell 
movements in greater detail and the underlying signalling mechanism. 
 
 
Figure 4: Hodgkin Lymphoma cell lines L428, KM-H2 and L1236 migrate with higher rates 
compared to several NHL cell lines. Migration of HL cell lines and NHL cell lines were measured 
in Boyden chamber assays (mean ± SD, n=3; DLBCL, BL: 16 h migration through 10 μm pores; 
MCL, HL: 6 h migration through 8 μm pores). Note the high migration rates of MCL and HL cell 
lines. From (Linke et al, 2016b). 
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3.1.1 cHL cells migrate in an amoeboid manner with special characteristics 
Since the above used assay for migration only measures endpoints of complex 
and very dynamic processes, time-lapse microscopy was applied to characterize 
cHL cell motility within a chemotactic gradient in greater detail and on single cell 
level. In 3D chemotaxis chambers L428 cells were completely embedded in 
type--collagen and their movements were monitored. L428 cells moved in an 
amoeboid way, which is composed of blebbing, polarization, deformation and 
translocation events (Figure 5). In detail, the cell started turning around quickly 
thereby forming short and long blebs in all directions as an initial part of 
movement. Then the cell appeared to concentrate with its cell body to a concrete 
point and formed a long and stretched constriction ring (barbell-like form). While 
the constriction ring formation appeared to require several minutes, the cell slipped 
forwards very fast from a particular point on and started blebbing again. 
 
Figure 5: cHL cells move with an amoeboid type of migration. Typical amoeboid type of 
migration of L428 cells is shown with two exemplary cells. Pictures were taken at 5 min intervals. 
Lower row: Schematic representation of the migration process consisting of blebbing, polarization, 
constriction ring formation and translocation (courtesy of Dr. Aldo Ferrari, ETH, Zurich) as 
introduced by (Friedl et al, 2001; Friedl & Wolf, 2003b). From (Linke et al, 2016b). 
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The observation of cHL single cell movements in connection with surrounding cells 
revealed additional characteristics. L428 cells seemed to be influenced by each 
other in their migration steps. For example, one initially non-moving cell (Figure 6 
A-G, black arrow) started moving towards another cell (white asterisk) in the 
moment this cell appeared in its z-axis (Figure 6 H). But cHL cells did not only 
appear to be attracted by each other, also cell-cell contacts seem to characterize 
their sequence of movements. One exemplary cell was frequently in close contact 
with surrounding cells before finally moving away (Figure 6 C-D, F-G, J, P; white 
arrow). Thus, mutual attraction and cell-cell contacts seem to be general 
characteristics of cHL cell movements and can be observed in all supplementary 
videos of control cells (Appendix; Supplementary Videos 1 and 5).  




Figure 6: Movements of cHL cells seem to be characterized by cell-cell contacts with 
neighbouring cells. Time-lapse microscopy of exemplary L428 cells over 230 min (A-T) revealed 
a typical behaviour of cHL cells. The marked cell (white arrow) continually contacts surrounding 
cells (e.g. in C, F, G, J) before moving ahead. One cell (white asterisk) moves into the frame (from 
H on) but starts leaving the frame in the z-axis direction from frame M on. The appearance of this 
cell (white asterisk) seems to initiate movements of another cell (black arrow) to that direction.  
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3.1.2 Inhibition of WNT ligand secretion reduces cHL cell migration, 
invasion and adhesion 
In order to analyse whether the observed high migration rates of cHL cells are 
associated with the WNT pathway the porcupine inhibitors, Wnt-C59 and IWP-2, 
were each applied to L428, KM-H2 and L1236 cells. Wnt-C59 as well as IWP-2 
block the palmitoylation of WNT ligands thus preventing their secretion and 
therefore autocrine signalling cascades (Proffitt & Virshup, 2012; Proffitt et al, 
2013).  
The migration rates of all three Wnt-C59- or IWP-2-treated cHL cell lines were at 
least reduced by up to 50 % compared to DMSO controls (Figure 7 A-F). By 
adding conditioned medium (CM) of untreated cHL cells the effects of porcupine 
inhibition were rescued. The cHL cells that were treated with both, the porcupine 
inhibitor and their respective CM, migrated with similar rates as the DMSO-treated 
or untreated cells (Figure 7 A-F). 
To exclude potential effects of the Wnt-C59 treatment on cHL cell viability and cell 
proliferation, MTT assays and cell doubling counting were performed. In contrast 
to the strong effect on cell migration Wnt-C59 and IWP-2 had no significant 
influence on cHL cell viability and proliferation with the applied concentrations 
(Figure 8 A-E). 




Figure 7: Migration of cHL cell lines depends on intact WNT ligand secretion. Migration of 
L428 (A), KM-H2 (B) and L1236 (C) cells after 72 h pre-treatment with 5 μM Wnt-C59 or DMSO is 
shown with (+CM) or without (-CM) the simultaneous stimulation with the respective 
cHL-conditioned medium for 24 h. Migration of L428 (D), KM-H2 (E) and L1236 (F) cells after 72 h 
pre-treatment with 5 μM IWP-2 or DMSO is presented with or without the simultaneous stimulation 
with the respective cHL-conditioned medium for 24 h. (mean ± SD, n=3, 1-way ANOVA and Dunn’s 
post-hoc test). Note that the inhibition of migration by porcupine inhibitors is rescued by CM 
addition (*P < 0.05, **P < 0.01 and ***P < 0.001). Modified from (Linke et al, 2016b). 




Figure 8: Porcupine inhibition does not significantly affect L428, KM-H2 and L1236 cell 
proliferation. Cell numbers of L428 (A), KM-H2 (B) and L1236 (C) cells are displayed after 
treatment with 5 μM Wnt-C59 or 5 μM IWP-2 for 72 hours. (mean ± SD, n=10 (L428; Wnt-C59 
p>0.99, IWP-2 p=0.723), n=8 (KM-H2, Wnt-C59 p=0.855, IWP-2 p>0.99), n=3 (L1236, Wnt-C59 
p>0.99, IWP-2 p=0.455), 1-way ANOVA and Bonferroni’s post-hoc test). MTT data of L428 (D) and 
KM-H2 (E) cells is shown after treatment with 5 μM Wnt-C59 for 72 hours. OD values of DMSO 
control were set as 1 (mean ± SD, n=4 (L428; p=0.4795), n=5 (KM-H2, p=0.2746), unpaired 
2-tailed t-test with Welch’s correction). Modified from (Linke et al, 2016b). 
Moreover, invasion of L428 and KM-H2 cells was measured after Wnt-C59 
treatment (Figure 9 A). Invasion rates through type--collagen significantly 
decreased to 50 % by porcupine inhibition. Since the adhesion capacity is an 
additional part of the whole invasion process adhesion of Wnt-C59-pre-treated 
L428 cells on endothelial cells as well as on type--collagen were also analysed 
(Figure 9 B). The amount of adherent cells on endothelial cells dropped to 30 % 
following Wnt-C59 treatment and to 40 % on type--collagen. These results 
indicate that cHL cells secrete WNT ligands in a porcupine dependent manner and 
these WNT ligands function in an autocrine way to stimulate cHL cell migration, 
invasion, and are also involved in adhesion processes. 




Figure 9: Invasion and adherence capacity of cHL cells is impaired after porcupine 
inhibition.  (A) Invasion of L428 or KM-H2 cells is presented after 72 h pre-treatment with 5 μM 
Wnt-C59 or DMSO (mean ± SD, n=3 2-way ANOVA and Bonferroni’s post-hoc test). (B) Adhesion 
of DMSO or Wnt-C59-pre-treated L428 cells is shown on either HUVEC (white) or type--collagen 
(grey) (mean ± SD, n=5, 2-way ANOVA and Bonferroni’s post-hoc test). Note the decrease of cell 
invasion and adhesion after WNT secretion inhibition (*P < 0.05, **P < 0.01 and ***P < 0.001). 
From (Linke et al, 2016b). 
3.1.3 Intervention of JAK/STAT, MAPK or NF-κB signalling does not perturb 
cHL cell migration  
To further evaluate the specificity of WNT signalling for cHL cell migration in 
comparison with other deregulated pathways of cHL cells, various chemical 
inhibitors or siRNAs were applied. The NF-κB, JAK/STAT and MAPK pathway 
were blocked at different levels. For the NF-κB pathway an IKK2 inhibitor (ACHP) 
was used and also IKK1 knockdown was performed. In addition, STAT3 was 
knocked down to test for the JAK/STAT pathway and, correspondingly, p38 
knockdown was performed to test for MAPK signalling. None of these 
interventions showed any effect on L428 cell migration (Figure 10) suggesting that 
WNT signalling is a highly specific regulator of cHL cell migration. 




Figure 10: Migration of L428 cells does not depend on NF-κB, JAK/STAT or MAPK 
signalling. (A) L428 migration was performed after 24 hours of treatment with 7 μM IKK2 inhibitor 
ACHP and 48 hours after IKK1, STAT3 or p38 (B) knockdown (mean ± SD, n=3, One-way ANOVA 
and Bonferroni’s post-test). Knockdown of STAT3 (C), IKK1 (D) and p38 (E) was evaluated with 
immunoblot assays using specific antibodies against STAT3 (C), IKK1 (D) or p38 (E) respectively. 
As loading control a specific antibody against tubulin was used (C-E). From (Linke et al, 2016b). 
3.1.4 Inhibition of the WNT ligand secretion impairs lymphoma outcome 
and vascularization in the in vivo CAM assay 
To test whether inhibition of Porcupine and consequently inhibition of autocrine 
WNT signalling affects not only migration and invasion of cHL cells in vitro but also 
cHL tumour outcome in vivo, the chick chorio-allantoic membrane (CAM) assay 
was applied as xenograft model. Wnt-C59-pre-treated L428 cells were inoculated 
on the CAM and four days later corresponding lymphomas were harvested. 
Lymphomas from L428 cells pre-treated with Wnt-C59 were significantly smaller 
compared to DMSO-pre-treated cells (Figure 11 A). To quantify lymphoma 
vascularization at the macroscopic level a vascularization score was established 
taking into account the appearance, intensity and relative area covered by the 
hemorrhage areas (Scoring hemorrhages in CAM tumours in chapter 2.12.16.4). 
Results    
62 
 
Based on this score the lymphomas developed from porcupine inhibitor-pre-
treated cHL cells were characterized by a lower degree of vascularization (Figure 
11 B).  
 
Figure 11: Treatment with porcupine inhibitors affects tumour size and hemorrhage scores 
in a chick CAM model. Tumour areas (A) of L428 tumours were measured and their 
corresponding hemorrhage scores (B) determined after three days of Wnt-C59 pre-treatment 
followed by four days of tumour growth on the CAM. Note the reduced tumour size and 
hemorrhages after porcupine inhibition. Exemplary tumour pictures are presented in Figure 12 und 
examples for the hemorrhage score in chapter 2.12.16.4 (DMSO, n=32; Wnt-C59, n=30; 2-way 
ANOVA and Bonferroni’s post-hoc test) (**P < 0.01 and ***P < 0.001). From (Linke et al, 2016b). 
In Figure 12 typical lymphomas derived from DMSO (A) or 
Wnt-C59 (B)-pre-treated L428 cells are presented, using 2 x 106 cells for 
inoculation. The H&E staining’s of these tumours (Figure 12 A-B) support the 
macroscopic observation of smaller tumour size and differences in vascularization. 
Bleeding, that was regularly observed in control tumours, was reduced in Wnt-
C59-pre-treated tumours. For detailed microscopic analysis ultra-thin sections 
were performed. As shown in Figure 12 C-D, DMSO control tumours showed 
massive signs of bleeding (asterisk) but still contained some perfused capillaries 
(red arrows). Wnt-C59-treated tumours contained low numbers of capillaries and, 
although vessels showed signs of disintegration (black arrow), hemorrhage was 
rarely visible. 
In addition to the classical analysis of morphology selected lymphoma were 
analysed by Micro-CT. In Figure 13 corresponding examples of DMSO or 
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Wnt-C59 pre-treated L428 lymphoma are shown. Both developed in close 
proximity to major vessels from the CAM. The CT scan revealed the existence of 
vessels with numerous branches in the DMSO controls (inlet Figure 3-10 A). Signs 
of vessel residuals as cause for large bleeding areas are indicated with black 
arrows. The Wnt-C59-pre-treated tumour showed no dominant branches although 
much smaller vessels were visible (inlet Figure 3-10 B). Micro-CT technique 
provides the view on many different virtual section planes thus visualizing vessel 
structures and their origin that would have been hardly to interpret with classical 
histology. Using H&E staining, ultra-thin sections and Micro-CT scans it can be 
concluded that autocrine WNT signalling is involved in lymphoma engraftment, 
affects lymphoma vascularization and suggests an additional paracrine WNT 
effect in cHLs. 
 
Figure 12: Porcupine inhibitor-treated CAM tumours show less hemorrhages. (A,B) 
Representative stereo-microscopic (7.8 x magnification) and H&E stained pictures of L428 tumours 
and (C,D) ultra-thin sections (bar= 5 μm) of KM-H2 cells treated with DMSO (A, C; ctr) or Wnt-C59 
(B, D; C59) are shown. Note strong bleedings (asterisk) and increased vessel numbers (red arrow) 
of control tumours and fragile vessels (black arrow) after porcupine inhibition. Modified from (Linke 
et al, 2016b). 




Figure 13: Porcupine inhibitor-treated CAM tumours contain less vessel structures. 
Micro-CT photos of selected L428 tumours that were treated with DMSO (A; ctr) or Wnt-C59 
(B; C59) are displayed. The white arrow points at a tumour-vessel which branches off a major CAM 
vessel in a control tumour. Black arrows show at vessel residuals in the control tumour (bar= 1mm). 
From (Linke et al, 2016b). 
3.1.5 WNT5A and WNT10B are expressed by cHL cells 
Since porcupine inhibition caused significantly reduced cHL migration rates (see 
chapter 3.1.1), the expression level of several WNT ligands that have already 
been correlated with an enhanced cell motility were tested (Qiang et al, 2005; 
Weeraratna et al, 2002; Long et al, 2015; Aprelikova et al, 2013). Therefore, the 
expression of WNT3A, WNT5A, WNT10A, WNT10B and WNT16 was analysed by 
qRT-PCR (Figure 14 A). L428 and KM-H2 cells expressed WNT5A and WNT10B, 
whereas WNT3A, WNT10A and WNT16 were not found. In addition, the amount of 
WNT5A was estimated by immunoblot assays as presented in Figure 14 B. 
WNT5A protein was detected in all tested HL cell lines with L1236 cells expressing 
the highest amounts. 




Figure 14: WNT5A is expressed in cHL cell lines on mRNA and protein level. (A) Relative 
WNT3A, WNT5A, WNT10A, WNT10B and WNT16 gene expression of L428, KM-H2 and L1236 
cells were measured by SYBRGreen qRT-PCR (mean ± errors, n=3, endogenous control: ABL). 
Note the high WNT5A and WNT10B expression in all three cell lines. (B) Western Blot reveals 
WNT5A protein expression in cHL cell lines using a specific antibody against WNT5A and against 
tubulin as loading control. From (Linke et al, 2016b). 
3.1.6 WNT5A signalling mediates migration and invasion in Hodgkin 
Lymphoma 
In order to identify migration-stimulating WNTs L428 cells were transfected with 
WNT-V5tag-containing pCDNA plasmids and subsequently their migration rates 
were determined. WNT5A, WNT10A, WNT10B and WNT16 were overexpressed 
in L428 cells. WNT5A overexpression increased L428 cell migration significantly 
by up to 50 % compared to vector controls (Figure 15 A). The overexpression of 
other migration-affecting WNTs like WNT10A, WNT10B and WNT16 had no effect 
on L428 migration (Figure 15 A). This highlights the dominant role of WNT5A for 
cHL migration. 
As proof-of-principle and to further confirm the special role of WNT5A for cHL cell 
motility, porcupine inhibitor-treated L428 cells were stimulated simultaneously with 
WNT5A L-cell-conditioned medium (WNT5A L-CM) in comparison to wildtype L-
cell-conditioned medium (L-CM) (Figure 15 B). WNT5A L-CM alone increased 
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L428 cell migration by approximately 75 %. The addition of WNT5A L-CM 
reversed the porcupine inhibitor-mediated inhibition of cHL cell migration 
significantly from 30 % back to almost 80 % of the controls. Consequently WNT5A 
can account for a major part of the porcupine-inhibitor rescue effect observed in 
Figure 7 albeit the rescue by the cHL conditioned medium was even stronger. 
As additional approach the WNT5A antagonist Box5 was used in cHL Boyden 
chamber assays. The treatment with Box5 reduced migration of L428, KM-H2 and 
L1236 cells by 25 to 50 % (Figure 15 C-E). Since porcupine inhibition did not only 
affect migration but also invasion and adhesion of cHL cells, additional invasion 
and adhesion assays were performed using Box5-pre-treated cells. Box5 
treatment reduced the invasion rates of L428 cells to 50 %, whereas exogenous 
recombinant WNT5A further increased invasiveness by 30-60 % (Figure 16 A). In 
addition, the specific WNT5A effect on the adhesion of L428 cells on endothelial 
cells (HUVEC) as well as type--collagen was tested with Box5. The fraction of 
adherent cells significantly decreased from 70 % to 40-30 % on HUVEC and to 
50 % on type--collagen when L428 cells were pre-treated with the WNT5A 
antagonist Box5 (Figure 16 B). These data suggest that WNT5A secreted by HL 
cells is at least one major activator of cHL cell migration, invasion and adherence.  




Figure 15: WNT5A is a stimulator of cHL cell migration. (A) Migration and Western Blot were 
performed with L428 cells transfected with pCDNA vector containing either WNT5A-V5-tag, 
WNT10A-V5, WNT10B-V5, WNT16-V5, or without insert. For protein detection specific antibodies 
against the V5-tag and against tubulin as loading control were used. (mean ± SD, n=3, 1-way 
ANOVA and Dunn’s post-hoc test). Note the exclusive effect of WNT5A. (B) Migration of L428 cells 
after Wnt-C59 treatment and application of wildtype (wt) or WNT5A L-cell-conditioned medium was 
analysed. Note the rescue effect observed with the simultaneous WNT5A L-CM treatment (mean ± 
SD, n=3, 2-way ANOVA and Bonferroni’s post-hoc test). L428 (C), KM-H2 (D) and L1236 (E) cells 
showed decreased migration rates after Box5 treatment (1 d, 100 μM) (mean ± SD, n=3, unpaired 
2-tailed t-test; for L428 with Welch’s correction) (*P < 0.05, **P < 0.01 and ***P < 0.001). Modified 
from (Linke et al, 2016b). 




Figure 16: Box5 inhibits WNT5A-mediated invasion and adhesion of L428 cells. (A) Invasion 
of L428 cells was reduced after Box5 treatment (1 d, 100 µM) but increased by WNT5A stimulation 
(1 d, 100 ng/ml) (mean ± SD, n=3, 1-way ANOVA and Bonferroni’s post-hoc test). (B) Adhesion of 
Box5 pre-treated L428 cells was reduced on either HUVEC cells (white) or type--collagen (grey) 
(mean ± SD, n=5, 2 way ANOVA and Bonferroni’s post-hoc test) (*P < 0.05, ***P < 0.001).  
3.1.7 Migration path characteristics depend on WNT5A signalling 
To further elucidate the effect of WNT5A signalling on cHL cell movements 
time-lapse studies of L428 cells in a three-dimensional collagen matrix were 
performed (Figure 17; overview images in the Appendix Figure A-43 A; 
Supplementary Videos 1-4). The majority of DMSO-treated control L428 cells 
migrated towards CCL19. However, numerous control cells moved slow or just 
turned in cycles while mostly actively blebbing. Others attracted attention due to 
high-speed movements. While the control cells showed a broad spectrum of these 
diverse types of movements, the inhibition of autocrine WNT signalling with Box5 
or Wnt-C59 was associated with an increase in the number of static cells and rare 
blebbing events. In contrast, stimulation with recombinant WNT5A further 
enhanced the degree of motility of all investigated cells. Blebbing and 
transformation events occurred with high dynamics.  




Figure 17: Wnt-C59, Box5 or WNT5A pre-treatment affects L428 cell movement paths in a 3D 
collagen matrix. Time-lapse microscopy of Wnt-C59, Box5 or WNT5A-pre-treated L428 cells was 
performed using IBIDI 3D chemotaxis chambers. Photos were taken every 5 min for 6 h. 
Representative coloured trajectories of single cells towards the chemoattractant are shown at 
indicated intervals. The chemokine was located on the right side. Corresponding Videos 1-4 can be 
found in the Appendix on page 151. 
Quantitative data analyses using trajectory dot plots support the video 
observations. The different treatments affected the directionality of cHL cell 
movements. The mean centres of masses of the track endpoints were significantly 
shifted towards the chemokine in the DMSO control and the WNT5A treatment 
groups, whereas they remained near the starting point in the Wnt-C59 and Box5 
treatment groups (Figure 18 A-D). Impaired WNT5A signalling also negatively 
affected the mean euclidean distances, accumulated distances and velocities 
(Figure 18 E-G). WNT5A stimulation further enhanced velocity from a mean of 
1.2 µm/min to 1.5 µm/min. 




Figure 18: WNT5A signalling influences cell path characteristics of L428 cells in a 3D matrix. 
Representative trajectory dot plots show the sector distribution of the L428 cells treated with DMSO 
(A), Wnt-C59 (B), Box5 (C) and WNT5A (D). For group directionality the centre of masses after 6 h 
is shown as yellow dot. CCL19 source was located on the right side. Velocities (E), euclidean (F) 
and accumulated (G) distances of DMSO, Wnt-C59, Box5 and WNT5A-pre-treated L428 cells were 
analysed (mean ± SD; DMSO, n=5; Wnt-C59, Box5, WNT5A, n=3 of each 50 trajectories; Kruskal-
Wallis test, ***P < 0.001). Note the inhibitory effects of Wnt-C59 and Box5 treatment while WNT5A 
stimulation enhances cell path characteristics. Corresponding Videos 1-4 can be found in the 
Appendix on page 151. Modified from (Linke et al, 2016b). 
In a next step the movement patterns of each cell towards the chemokine were 
converted into biostatistical fingerprints. The fingerprints of the inhibitor-treated 
(Wnt-C59, Box5) or WNT5A-stimulated groups were hierarchically ordered 
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according to highest similarities (Figure 19 A). Next to the similarity-dendrogram 
examples of the movement classes belonging to the corresponding subgroups are 
plotted. In the heat map the movement patterns of the Wnt-C59 (black) and Box5 
(green) inhibitor-treated groups clearly separate from the WNT5A group (orange) 
as shown in Figure 19 A (heat map including DMSO datasets are presented in the 
appendix Figure A-43 B).  
To further dissect the influence of WNT5A on cellular movement patterns the 
relative distribution of each treatment group within the six most different movement 
classes was calculated (Figure 19 B). These classes include non-moving 
(class 1), turning (class 2), initially not moving (class 3), short (class 4) and long 
distances (class 5, class 6 with twists) covering cells. Movement classes 3 and 6 
occurred only rarely and were almost only seen in the control and WNT5A-
stimulated groups. 37 % of DMSO control cells covered short distances (class 4) 
within 6 hours whereas approximately 20 % had not moved (class 1) or covered 
long distances in a directed manner (class 5). This distribution shifted after 
Wnt-C59 or Box5 treatment. In the inhibitor-treated groups 60-70 % of the cells 
belonged to movement class 1, or had mainly turned around (class 2). Long 
distance tracks occurred less than half as often as in the control group (classes 5, 
6). In contrast the WNT5A stimulation shifted the group distribution towards the 
long-distance track groups (classes 5, 6). Approximately half of the cells of the 
WNT5A group covered directed long distances (classes 5 and 6), while the 
number of non-moving cells was cut by half compared to the DMSO controls. 
Thus, time-lapse microscopy further underlines the motility shaping properties of 
WNT5A for cHL cells. 




Figure 19: L428 cell movement classes are affected by WNT5A signalling. (A) The heat map 
displays the results of the hierarchical clustering of movement patterns of Wnt-C59, Box5 or 
WNT5A-treated L428 cells based on shape fingerprints according to the form and length of each 
track. Exemplary fingerprints are plotted next to their corresponding position in the dendrogram and 
are shown as track coordinates and shape fingerprint. The x-axis of the heat map corresponds to 
the internal distances within single tracks, with short distances mapped to the left and longer 
distances to the right. The colour of the heat map tiles represents the number of counts for specific 
distances per track ('square root transformed' to enhance contrast). Experimental group 
membership is encoded by colours on the left side of the heat map with black (Wnt-C59), green 
(Box5) and orange (WNT5A). (B) Relative distribution of the six most different movement classes 
within each group of DMSO, Wnt-C59, Box5 or WNT5A-treated L428 cells. Corresponding Videos 
1-4 can be found in the Appendix on page 151. From (Linke et al, 2016b). 
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3.1.8 FZD5 and DVL3 are required for cHL cell migration 
For the dissection of mechanisms required for the WNT5A-mediated cHL 
migration, selected components of the PCP pathway were analysed including 
FZD5. FZD5 is one of the known high-affinity WNT5A receptors (Dijksterhuis et al, 
2015). Knockdown of FZD5 significantly decreased the migration rates of the two 
cHL cell lines, L428 and KM-H2 (Figure 20 A-B; Appendix Figure A-44 A). 
Therefore, FZD5 is an important PCP receptor involved in cHL cell migration. 
 
Figure 20: FZD5 knockdown impairs L428 cell migration. (A) Migration is significantly reduced 
in L428 cells 48 h after FZD5 knockdown (mean ± SD, n=3, unpaired 2-tailed t-test with Welch’s 
correction, ***P < 0.001). (B) Corresponding Western Blot shows the FZD5 knockdown in L428 
cells. Protein was detected using specific antibodies against FZD5 and against GAPDH as loading 
control. From (Linke et al, 2016b).  
Next, the role of the FZD-associated cytoplasmic adaptor protein DVL was 
investigated. KM-H2 and L428 cells were stimulated with WNT5A and the 
activation status of DVL1, DVL2 and DVL3 was monitored by the existence of the 
second shifted activation band of DVL in immunoblots over the time (Figure 21 A, 
Appendix Figure A-44 B). DVL1 was slightly active and could not be further 
activated by WNT5A stimulation over the time. In addition, DVL2 was almost 
completely activated in control cells and could not further be activated. In contrast 
DVL3 was specifically activated after WNT5A stimulation. The activation maximum 
seemed to be reached after one hour in KM-H2 cells and after 30 minutes in L428 
cells. As further confirmation WNT5A stimulation induced specific activation of 
DVL3 already after 10 minutes in all three cHL cell lines used  (Figure 21 B), while 
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this activation was abolished by treating cells with the WNT5A antagonist Box5 
(Appendix Figure A-44 C). 
 
Figure 21: DVL3 is exclusively activated in a time-dependent manner after WNT5A 
stimulation in cHL cells. (A) Western Blot of KM-H2 cells stimulated with 100 ng/ml recombinant 
WNT5A for the indicated time intervals. Note the increasing activation of DVL3 during the first hour. 
(B) Western blot of L428, KM-H2 and L1236 cells after stimulation with 100 ng/ml recombinant 
WNT5A or PBS/BSA for 10 minutes. Note the increase of active DVL3 after WNT5A stimulation. 
For protein detection (A, B) specific antibodies against DVL1, DVL2, DVL3 and against tubulin or 
GAPDH as loading control were used. Modified from (Linke et al, 2016b). 
In order to further investigate the role of DVL3 for cHL cell migration DVL3 
knockdown as well as overexpression was performed. DVL3 knockdown alone 
reduced L428 cell migration by up to 30 % (Figure 22 A). In addition, the 
overexpression of wildtype DVL3 enhanced L428 migration by up to 27%, whereas 
the dominant-negative DVL3 variant (DVL3-K435M), that cannot interact with FZD 
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anymore (Axelrod et al, 1998), significantly reduced L428 migration by 
approximately 26 % (Figure 22 B). Consequently, DVL3 is an important mediator 
of cHL cell migration. 
 
Figure 22: DVL3 expression is required for L428 cell migration. (A) Migration and Western blot 
of L428 cells were performed 48 h after DVL3 knockdown. Note the inhibitory effect of the DVL3 
knockdown on L428 cell migration. (mean ± SD, n=3, unpaired 2-tailed t-test). (B) Migration and 
Western blot of L428 cells were shown 48 h after transfection with DVL3 wildtype or the dominant 
negative DVL3K435M variant. Note the migration-stimulating effect of DVL3 wildtype 
overexpression while the dominant negative DVL3K435M variant reduces L428 cell migration. For 
protein detection (A,B) specific antibodies against DVL3 and against tubulin or GAPDH as loading 
control were used. (mean ± SD, n=3, 1-way ANOVA and Bonferroni’s post-hoc test) (***P < 0.001). 
From (Linke et al, 2016b). 
3.1.9 WNT5A on extracellular vesicles (EVs) activates DVL3 and stimulates 
cHL cell migration 
Since WNT ligands can be secreted on EVs such vesicles were isolated from the 
supernatant of untreated L428 and KM-H2 cells. WNT5A was detected in the EVs 
of L428 and KM-H2 cells (Figure 23 A). To further confirm that WNT5A protein is 
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secreted on EVs by cHL cells, L428 cells were transfected with WNT5A-V5tag-
containing or control pCDNA plasmids. Actually, the V5-tag was detected in the 
EVs of the WNT5A overexpressing L428 cells (Figure 23 B). To assess whether 
the EV of cHL cells can induce similar pathways as recombinant WNT5A 
stimulation or WNT5A overexpression, L428 and KM-H2 cells were stimulated with 
their EVs for 24 hours.  Stimulation of L428 and KM-H2 cells with their EVs for 10 
minutes activated DVL3 and also slightly DVL1 in the KM-H2 cells (Figure 23 C). 
Stimulation with EVs increased migration of L428 and KM-H2 cells up to 30 % 
(Figure 23 D), further confirming the autocrine migration stimulating feedback loop 
of cHLs. 
 
Figure 23: WNT5A of EVs activates DVL3 and stimulates cHL migration. (A) WNT5A is 
expressed on L428 and KM-H2 EVs. For WNT5A protein detection a specific antibody against 
WNT5A was used. (B) WNT5A-V5 is expressed on L428 EVs after transfecting cells with the 
corresponding pCDNA plasmid. For protein detection on EVs a specific antibody against the V5 tag 
was applied. (C) Western blot of L428 and KM-H2 cells after stimulation with EVs for 10 minutes. 
Note the increase of active DVL3 after EV stimulation. For protein detection specific antibodies 
against DVL1, DVL2, DVL3 and against tubulin as loading control were used. (D) Migration of L428 
cells is increased after stimulation with their EVs for 24 hours. (mean ± SD, n=3, unpaired 2-tailed 
t-test). (***P < 0.001) 
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3.1.10 RHOA is activated after WNT5A stimulation  
Next, the activation of the small GTPase RHOA by WNT5A was investigated. 
Protein pulldown assays of activated RHOA were performed. WNT5A stimulation 
of L428 cells activated RHOA within 5 minutes and continued for at least 15 
minutes on a high level (Figure 24 A). To investigate whether RHOA activation 
depends not only on WNT5A stimulation but also on FZD5 or DVL3 expression, 
the RHOA pulldown assay was repeated with L428 knockdown cells. As monitored 
in three independent pulldown assays knockdown of DVL3 or FZD5 abolished 
WNT5A-mediated RHOA activation almost completely (Figure 24 B) thereby 
implying that RHOA activation after WNT5A stimulation depends on FZD5 and 
DVL3 signalling. 
 
Figure 24: WNT5A stimulates RHOA in a DVL3 and FZD5-dependent manner. Western blot 
using specific anti-RHOA antibodies after RHOA-GTP pulldown of WNT5A-stimulated L428 cells 
alone (A) and after DVL3 and FZD5 knockdown (B) was performed. (C) Western blot intensities of 
three independent assays have been measured using ImageJ (mean ± SD, n=3, 2-way ANOVA 
and Bonferroni’s post-hoc test, **P < 0.01). Note the increase of activated RHOA over the time that 
almost completely disappears under DVL3 or FZD5 knockdown. From (Linke et al, 2016b). 
As RHOA activates ROCK two different ROCK inhibitors, Y-27632 and H1152P, 
were applied. Both ROCK inhibitors blocked migration rates of L428 cells almost 
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completely without affecting cell viability (Figure 25 A-B) suggesting an important 
role of ROCK for cHL cell motility.   
 
Figure 25: L428 cell migration depends on ROCK (A) Migration of L428 cells is impaired after 
ROCK inhibition using 5 μM Y-27632 or 0.5 μM H1152P (mean ± SD, n=3, 1-way ANOVA and 
Bonferroni’s post-hoc test). (B) MTT of L428 cells after treatment with 5 μM Y27632 or 0.5 μM 
H1152P for 72 hours was performed. OD values of DMSO control have been set 1 (mean ± SD, 
n=4 (Y27632 p=0.4717, H1152P p>0.999), One-way ANOVA and Bonferroni’s post-hoc test) 
(***P < 0.001). Modified from (Linke et al, 2016b). 
3.1.11 WNT5A expression is increased in a fraction of patients and 
associated with early relapse cases 
Since the in vitro results suggest a lymphoma-promoting role of WNT5A publically 
available microarray data of WNT5A gene expression in cHL was analyzed. By 
using the Brune Lymphoma data set WNT5A expression was compared between 
a subset of physiological B-cells and several lymphoma entities (Brune et al, 
2008). WNT5A expression is increased in the analysed primary HRS cells of a 
considerable number of patients (Figure 26 A). These patient’s data are in line 
with the in vitro cHL cell line results on aberrant WNT5A expression by cHL cells.  
By using a second data set by Steidl et al. WNT5A gene expression was also 
correlated with clinical parameters (Steidl et al, 2010a). WNT5A expression is 
significantly increased in patients with early relapse compared to late relapses 
(P=0.037) (Figure 26 B). This implies that enhanced WNT5A expression might 
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also correlate with a worse clinical outcome by contributing to early relapses of 
aggressive cHL cases. 
 
Figure 26: WNT5A expression is increased in a substantial fraction of cHL patients. (A) 
WNT5A expression is high in several HRS patients’ samples (no. 9). WNT5A expression data was 
obtained by single HRS cell analysis by Brune et al. (Brune et al, 2008) (mean of single patients’ 
data; No.1: centroblasts n=5; No.2: memory B-cell n=5; No.3: naïve pre-germinal centre B-cell n=5; 
No.4: plasma cell n=5; No.5: small cleaved follicle centre cell n=5; No.6: BL n=5; No.7: DLBCL 
n=11; No.8: Follicular lymphoma n=5; No.9: HL n=12; No.10: nodular lymphocyte predominant HL 
n=5). (B) WNT5A expression is significantly increased in patients with early relapse compared to 
late relapse. WNT5A expression data obtained by Steidl et al. (Steidl et al, 2010a) (mean ± SD, 
early, n=9; late, n=19; refractory, n=10; Mann-Whitney test) (*P < 0.05). From (Linke et al, 2016b). 
3.1.12 Autocrine canonical WNT signalling is detected in cHL cells 
Since non-canonical WNT5A signalling has been shown to play a pivotal role for 
cHL cell motility, the question arose whether canonical WNT signalling might also 
be important for cHL cells. The activation of canonical WNT signalling can be 
monitored by nuclear translocation of β-catenin. Western Blot analysis of the 
cytosolic and nuclear localization of β-catenin revealed that albeit at low levels a 
substantial proportion is already localized within the nucleus (Figure 27). As 
control L428 cells were stimulated with a typical canonical WNT, WNT3A, which 
further stimulated β-catenin translocation, while the non-canonical WNT ligand 
WNT5A did not further increase the nuclear amount of β-catenin. Interestingly, 
nuclear β-catenin translocation was also enhanced after stimulation with 
conditioned medium of L428 cells suggesting an autocrine canonical WNT 
pathway activity in cHL cells. 




Figure 27: Low amounts of β-catenin are already located in the nucleus of L428 cells. 
Western Blot of cytosolic and nuclear fractions of L428 cells stimulated with 24 h or 48 h 
conditioned medium (CM) shows increased nuclear β-catenin fraction after CM stimulation. For 
protein detection specific antibodies against β-catenin and against HDAC as nuclear control and 
HSP90 as cytosolic control were used. Modified from (Linke et al, 2016a). 
3.1.13 Increased LEF-1 expression is associated with B-cell malignancies  
Since LEF-1 can form a transcription complex with β-catenin in the nucleus, the 
hypothesis was tested whether LEF-1 expression might be a general marker for 
lymphomas and especially cHLs. Interestingly, the analysis of publically available 
gene expression data sets showed that increased expression of LEF-1 in cHL is 
comparable to CLL or BL cases (Basso et al, 2005) (Figure 28 A). As the Basso 
data set only comprised cHL data of four cell lines an additional data set with 
patients’ data was analysed. In the Brune data set it is found that cHL LEF-1 
expression is significantly increased in comparison to a set of normal B-cells 
including memory and germinal centre B-cells (Brune et al, 2008) (Figure 28 B) 
suggesting an aberrant expression of LEF-1. 




Figure 28: Aberrant LEF-1 expression in lymphoma entities compared to physiological 
B-cell subsets. LEF-1 expression data obtained by Basso et al. (Basso et al, 2005) (A) and Brune 
et al. (Brune et al, 2008) (B). Aberrant LEF-1 expression is increased in analysed lymphoma and 
leukaemia (A) and significantly higher in cHL patient samples compared to physiological B-cells (B) 
(mean ± SD, Basso et al.: B-Lymphocyte, Naive Pre-GC B-Lymphocyte, Memory B-Lymphocyte, 
Centroblast, each n=5; BL, n=31; HL, n=4 (cell lines); DLBCL, n=41; CLL, n=34; Brune et al.: Naive 
Pre-GC B-Lymphocyte, Memory B-Lymphocyte, Small Cleaved Follicle Centre Cell, Centroblast, 
Plasma Cell, n=5; HL, n=12 (patients’ material); 1-way ANOVA and Bonferroni’s post-hoc test, **P 
< 0.01 and ***P < 0.001). From (Linke et al, 2016a). 
3.1.14 Inhibition of the canonical WNT pathway reduces cHL cell 
chemotaxis  
To test the impact of canonical WNT signalling on cHL cell migration the signalling 
cascade was inhibited at different levels of signal transduction. The antagonisation 
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of WNT receptor binding with DKK1 and DKK2 reduced chemokine-mediated cHL 
cell chemotaxis to 80 % in single treatments and to 68 % in combination (Figure 
29 A). To target the canonical β-catenin destruction complex CK1 or tankyrases 
were inhibited. These inhibitors prohibit the disassembly or stabilize the β-catenin 
destruction complex respectively, thus causing a permanent cytosolic degradation 
of β-catenin. For migration assays cHL cells were incubated with 50 nM PF670462 
or 5 μM XAV939 for 24 hours. As functional test nuclear and cytosolic fractions 
were prepared from inhibitor-treated cells. Application of CK1 or tankyrases 
inhibitor reduced the basal nuclear β-catenin fraction and even WNT3A stimulation 
did no longer stimulate β-catenin translocation under inhibitor treatment (Appendix: 
Figure A-45). In modified Boyden chamber assays the inhibition of CK1 or 
tankyrases led to a reduction of cell chemotaxis rates to 55 % and 76 % 
respectively (Figure 29 B).  
 
Figure 29: Inhibition of the canonical WNT signalling decreases cHL cell migration. (A) 
Migration of L428 and KM-H2 cells is decreased after 24 h of pre-treatment with 100 ng/ml DKK1, 
DKK2 or DKK1 plus DKK2. (mean ± SD, n=3; 2-way ANOVA and Bonferroni’s post-hoc test, 
significance level is shown compared to respective PBS/BSA control). (B) Migration of L428 cells is 
decreased after 24 h of pre-treatment with 5 µM XAV939 or 0.05 µM PF670462 (mean ± SD, 
XAV939, n=4; PF670462, n=3; 2-way ANOVA and Bonferroni’s post-hoc test) (**P < 0.01 and 
***P < 0.001). From (Linke et al, 2016a). 




Figure 30: Inhibition of the canonical WNT pathway does not affect cHL cell proliferation. 
Relative cell numbers of L428 and KM-H2 did not change after 24 hours of treatment with DKK1 
and DKK2 (A), PF670462 and XAV939 (B). Of note, no significant difference in cell proliferation 
has been caused by inhibitor treatments (mean ± SD, n=3, 2-way ANOVA with Bonferroni’s post-
hoc test). From (Linke et al, 2016a). 
To exclude potential effects of the DKK, XAV939 or PF670462 treatment on cHL 
cell proliferation, cHL cells were counted after the respective inhibitor treatment 
but no effects on cell numbers have been detected (Figure 30).  
At transcription factor level both, transient and stable, knockdowns of LEF-1 as 
well as transient knockdown of β-catenin were performed. Migration rates were 
measured two days after transient nucleofection or puromycin-free culture of L428 
and KM-H2 pGIPZ cell lines. Knockdowns of LEF-1 as well as β-catenin reduced 
cHL chemotaxis rates by approximately 30 % (Figure 31 A-D). To exclude that 
reduced LEF-1 expression is compensated by the upregulation of other TCF 
factors RNA and protein levels of TCF7 (TCF1), TCF7L1 (TCF3) and TCF7L2 
(TCF4) were controlled in LEF-1 knockdown cell lines but no clear compensation 
was detected (Appendix: Figure A-46).  
In addition, invasion through type--collagen was also investigated in modified 
Boyden chamber assays using type--collagen-coated membranes. Invasion was 
significantly impaired by LEF-1 and β-catenin knockdown (Figure 31 E). In 
comparison to the migration assays with uncoated membranes the inhibition effect 
in the invasion assay was even bigger. These data further support the hypothesis 
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that canonical WNT signalling is linked to cHL cell migration and invasion and 
therefore part of the cHL motility relevant signalling cascades. 
 
Figure 31: LEF-1 and β-catenin expression are necessary for cHL cell migration and 
invasion. Migration rates of L428 and KM-H2 cells after stable (A, B) and transient LEF-1 (C) or 
β-catenin (D) knockdown are reduced. For protein detection specific antibodies against LEF-1, 
β-catenin and against GAPDH or tubulin as loading control were used. (mean ± SD, LEF-1 si, n=4; 
β-catenin si, n=3; unpaired, 2-tailed t-test). (E) Invasion through type--collagen is decreased in 
L428 and KM-H2 LEF-1 and β-catenin knockdown cells. (mean ± SD, n=3, 1-way ANOVA and 
Bonferroni’s post-hoc test, significance level is shown compared to respective scr si control) 
(**P < 0.01 and ***P < 0.001). Modified from (Linke et al, 2016a). 
Since the CM of cHL cells as well as WNT5A was capable to rescue the porcupine 
inhibitor effect on cHL cell migration (Figure 7 and Figure 15 B), the effect of 
WNT5A on cHL cells with an inhibited canonical WNT signalling was also tested. 
Of note, the simultaneous WNT5A stimulation rescued the migration impairment 
by the application of the canonical WNT signalling inhibitor XAV939, but not the 
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Y-27632-mediated inhibition of L428 cell migration (Figure 32). This suggests that 
WNT5A signalling relies on functional ROCK kinases but acts independent of 
canonical WNT signalling. 
 
Figure 32: WNT5A can rescue inhibition of tankyrases but not ROCK. Migration of L428 cells 
was measured after Y-27632 or XAV939 treatment and stimulation with wildtype (wt) or WNT5A 
L-cell-conditioned medium (WNT5A L-CM) (mean ± SD, n=3, 2-way ANOVA and Bonferroni’s 
post-hoc test). Note the rescue of XAV939-treated cells by WNT5A stimulation (***P < 0.001). 
Modified from (Linke et al, 2016b). 
3.1.15 Migration path characteristics of cHL cells are impaired after LEF-1 
and β-catenin knockdown 
To assess the influence of the LEF-1 or β-catenin knockdown on the typical cHL 
cell movement characteristics, siRNA-treated KM-H2 cells were monitored over 
6 hours and their corresponding cell tracks were analysed (Appendix 
Supplementary Videos 5-7). Fifty cells per condition were tracked in each 
biological experiment. Many control (scr si) KM-H2 cells moved in an amoeboid 
manner and very directed towards the CCL19 gradient, while others were at least 
actively blebbing and turning around in the gel (Figure 33 A). In contrast many 
LEF-1 as well as β-catenin knockdown KM-H2 cells seemed to have difficulties to 
orientate correctly and squeezed in different directions before moving. Therefore, 
knockdown cells lacked directness in their movements (Figure 33 A). One 
exemplary cell for each group is shown in Figure 33 A below the trajectory dot 
plots. While control cells most often blebbed, orientated and squeezed in short 
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time intervals, LEF-1 and especially β-catenin knockdown cells needed the same 
time interval for squeezing and turning around without moving much apart from 
their starting point (Figure 33 A red cross). The further analysis of whole group 
movements strengthened this impression. Cell velocities were significantly 
reduced from 1.1 µm/min to 0.6 µm/min and 0.4 µm/min due to LEF-1 and 
β-catenin knockdown respectively (Figure 33 B). Similarly, covered distances 
including euclidean and accumulated distances decreased strongly compared to 
control KM-H2 cells to approximately 30 % and 50 % respectively (Figure 33 C-
D). 
 
Figure 33: LEF-1 and β-catenin influence cell path characteristics of cHL cells in a 3D 
matrix. KM-H2 scr si control, LEF-1 and β-catenin knockdown cells have been embedded in type--
collagen in μ-Slide chemotaxis
3D
 chambers and their cell tracks have been observed using time-
lapse microscopy. (A) Representative trajectory dot plots show the sector distribution of control 
scr si, LEF-1 and β-catenin knockdown cells. Single cell tracks covering more than 75 μm 
euclidean distance are coloured red. For group directionality the centre of masses is shown as 
yellow dot. The triangle CCL19 indicates the chemokine gradient. Beneath the dot plot one 
representative cell movement is shown over the time. Note the impaired directionality in LEF-1 and 
β-catenin knockdown cells. Velocities (B), euclidean (C) and accumulated distances (D) of LEF-1 
and β-catenin knockdown cells are significantly reduced compared to control scr si cells (mean ± 
SD; n=3 of each 50 trajectories; Kruskal-Wallis test, ***P < 0.001). Corresponding Videos 5-7 can 
be found in the Appendix on page 151. From (Linke et al, 2016a). 
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Next, each cell track was converted into a biostatistical fingerprint which allows the 
comparison of the track patterns and characteristics between control (scr si) and 
LEF-1 and β-catenin knockdown KM-H2 cells in a very detailed manner for all cells 
tracks acquired throughout the different biological replicates. Therefore, the single 
cell tracks of each treatment group were hierarchically ordered according to 
highest similarities. In the similarity heat map the tracks of control (scr si) cells 
clearly separated from knockdown cells suggesting huge path differences 
throughout these cell groups (Appendix: Figure A-47).  
By hierarchical clustering the 15 most different movement classes were calculated 
and analysed (Figure 34). Control KM-H2 cells showed a particular pattern 
concerning the distribution throughout these 15 movement classes and the effect 
of LEF-1 and β-catenin knockdown on this particular distribution was investigated. 
The precise paths KM-H2 cells used to move through the matrix were very 
divergent. Several cell tracks were composed of more or less straight and long 
single steps (classes 12-15) that were strikingly overrepresented by control cells. 
Other classes consisted almost entirely of very short steps up to halts (classes 
8-11) and were predominantly represented by the LEF-1 and β-catenin knockdown 
cells. The third group of movement classes (1-7) contained many short steps but 
also already intermediate steps and were found in all cell groups. Of note classes 
8-11 display tracks with several halts and short back and forth steps. These 
movements are not continuous and always interrupted. Since these classes were 
predominantly found in knockdown cells these classes might be characteristic for 
motility and orientation impairments. This leads to the hypothesis that canonical 
WNT signalling is required for directed cell movements and affects not only 
covered distance lengths and velocity but might also be of importance for cell 
paths in general. 




Figure 34: LEF-1 and β-catenin influence movement classes of cHL cells in a 3D matrix. The 
15 most different movement classes out of 450 cell tracks are shown and the corresponding 
distribution within each group of scr si, LEF-1 si and β-catenin si KM-H2 cells. Classes 8-11 
characterized by low directionality are dominant for LEF-1 si and β-catenin si KM-H2 cells. 
Corresponding Videos 5-7 can be found in the Appendix on page 151. From (Linke et al, 2016a). 
3.2 cHL cells possess pro-angiogenic properties that depend on 
WNT signalling  
Since cHL cells are embedded in an infiltrate of immune and stroma cells, not only 
their own motility is relevant for lymphoma progression but also the direct 
manipulation of endothelial cells. If alterations of endothelial cells are considered 
as an important step in lymphoma dissemination it is important to test the influence 
of HRS cells on endothelial cell features. To model the initial sprouting of vessels 
the spheroid assay was applied. HUVEC spheroids embedded with LEF-1 
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deficient cHL CM sprouted only half as often compared to control cHL CM (Figure 
35 A-B). But if sprouting events occurred, neither the number of sprouting tips nor 
the cumulative sprout length differed between LEF-1 knockdown CM spheroids 
and control CM spheroids (Figure 35 C-D). This suggests that LEF-1 might 
regulate the secretome of cHLs for the initialization of the endothelial sprouting 
event rather than defining its characteristics. 
 
Figure 35: LEF-1 and β-catenin modify the influence of cHL cells on endothelial cell 
sprouting. (A) Representative pictures of sprouting HUVEC spheroids grown in CM of KM-H2 ns 
control or LEF-1 knockdown cells are shown (100-fold magnification). As positive control cell 
culture medium- has been used. For analysis the frequency of sprouting events (B), the 
cumulative sprout lengths (C) and the number of sprouting tips (D) have been calculated. Note the 
only difference between control and LEF-1 knockdown CM is the sprouting frequency. Spheroids 
grown in RPMI medium do not sprout. (mean ± SD, n=3 of each 12-20 spheroids). From (Linke et 
al, 2016a). 
In the next step of angiogenesis a lumen has to be formed by the endothelial cells. 
This was modelled with tube formation assays. Therefore, the HUVEC capacity to 
form tubes on a gel composed similar to the extracellular matrix was analysed. 
HUVEC cells in LEF-1 or β-catenin knockdown cHL CM formed tubes, but the tube 
lengths were significantly reduced compared to the control cHL CM (Figure 
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36 A-B). Thus, the LEF-1/β-catenin-regulated secreted factors are also involved in 
the vessel lumen formation process. 
 
Figure 36: LEF-1 and β-catenin modify the influence of cHL cells on endothelial tube 
formation. (A) Representative pictures of HUVEC tubes formed in KM-H2 scrambled control, 
LEF-1 or β-catenin knockdown CM are displayed (100-fold magnification). As positive control cell 
culture medium- has been used. In pure RPMI medium HUVEC cells do not form any tubes. (B) 
For quantification cumulative tube lengths have been measured. Cumulative tube lengths are 
significantly reduced in HUVEC cells treated with CM of KM-H2 LEF-1 or β-catenin knockdown 
cells. (mean ± SD, n=3 of each 4 wells; 1-way ANOVA and Bonferroni’s post-hoc test, **P < 0.01). 
From (Linke et al, 2016a). 
3.2.1 Inhibition of the canonical WNT pathway impairs lymphoma outcome 
and vascularization in the in vivo CAM assay 
Since angiogenesis is a very complex and multi-step process, in vitro assays, 
which analyse single mechanisms, are limited. A very well established system to 
monitor the whole angiogenesis process and thus the impact of single cell 
components on vessel formation and destruction is the CAM assay as already 
described in chapter 3.1.4.  The tankyrases inhibitor XAV939, which promotes the 
canonical destruction complex and thus inhibits nuclear β-catenin translocation, 
was applied to L428 cells. Exemplary L428 tumours are presented in Figure 
37-A-B. Measurement of the tumour area as well as evaluation of the 
hemorrhages in a blinded manner revealed that tumours derived from 
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inhibitor-treated cells were significantly smaller and showed less hemorrhages 
(Figure 37 C-D).  
In addition Micro-CT technique was applied to virtually cut the tumour in order to 
monitor the vessel network within the whole tumour mass (Figure 38 A). 
DMSO-treated control tumours were interspersed with vessels and vessel 
residuals (Figure 38 B-C left). Interestingly, new vessels originated inside the 
tumour out of an already existing big CAM vessel of the tumour surface with 
several ramifications (Figure 38 D). In contrast, the tankyrases inhibitor-treated 
tumours were not able to build up such a complex vessel network inside the 
tumour mass (Figure 38 E). Consequently the results of the in vivo CAM assay 
are in line with the in vitro angiogenesis assays by showing a remarkable impact of 
canonical WNT signalling of cHLs on the endothelial vasculature. 
 
 
Figure 37: Impaired canonical WNT signalling by XAV939 treatment affects lymphoma 
outcome in the chick CAM assay. L428 cells were pre-treated for 24 hours with XAV939, 
inoculated on the CAM and harvested after four days of tumour growth. Representative 
stereo-microscopic photos (7.8 x magnification) show L428 tumours treated with DMSO (A) or 
XAV939 (B). Note decreased size and reduced bleedings in XAV939-treated tumours. To quantify 
the lymphoma outcome tumour area (C) of L428 tumours and the corresponding hemorrhage score 
(D) have been measured (mean ± SD, L428 DMSO, n=19; L428 XAV939, n=21; A: 2-way ANOVA 
and Bonferroni’s post-hoc test, B: Mann-Whitney test) (*P < 0.05, **P < 0.01). Modified from (Linke 
et al, 2016a). 




Figure 38: Impaired canonical WNT signalling by XAV939 treatment reduces lymphoma 
hemorrhages. (A-C) Volume rendered Micro-CT data sets show exemplary KM-H2 tumours 
pre-treated with DMSO (left) or XAV939 (right) (B-E: virtually cut open). Black arrows indicate 
vessel structure inside the tumours. In comparison to control DMSO tumours (D) the vessel 
network in the XAV939-treated tumour (E) is reduced despite CAM vessel access (bar=3 mm). 
Modified from (Linke et al, 2016a). 
3.2.2 WNT5A addition enhances cHL tumour hemorrhages in the in vivo 
CAM model 
Porcupine inhibition as well as the inhibition of the canonical WNT pathway had a 
strong effect on the vasculature of in vivo cHL tumours (Figure 11 and Figure 37). 
Next, it was tested whether also WNT5A stimulation could affect cHL lymphoma 
engraftment by using WNT5A pre-stimulated cHL cells. L428 cells were stimulated 
with either recombinant WNT5A protein or WNT5A L-CM 24 hours prior to the 
inoculation. Since endogenous canonical and non-canonical WNT signalling was 
not blocked, the PBS and wt-L-CM controls still possessed autocrine WNT 
signalling. Regarding the results from the Wnt-C59 experiments (3.1.2 and 3.1.4) it 
was hypothesized that additional exogenous WNT5A stimulation could further 
promote lymphoma formation, as it was also observed for cell motility and velocity 
in vitro. Tumours derived from recombinant WNT5A or WNT5A L-CM pre-treated 
L428 cells were bigger and had increased hemorrhages compared to control 
tumours (Figure 39 A-B). Semi-thin sections of the corresponding CAM tumours 
illustrate the further increased bleeding areas induced by additional WNT5A 
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stimulation (Figure 39 C-D). Although the L428 control tumours already 
possessed hemorrhages, the additional increase by WNT5A depicts a high 
potential for vessel disruption and vessel remodelling capacity. 
 
Figure 39: WNT5A pre-treatment positively affects tumour outcome in a chick CAM model. 
Tumour area (A) of L428 tumours and the corresponding hemorrhage scores were determined (B) 
after 24 h of pre-treatment with either WNT5A L-cell-conditioned medium (L-CM) or 100 ng/ml 
recombinant WNT5A protein and four days of tumour growth on the CAM. Note the increase of 
tumour size and hemorrhages after WNT5A stimulation (PBS, n=11; WNT5Arec, n=10; wt L-CM, 
n=36; WNT5A L-CM, n=37, 2-way ANOVA and Bonferroni’s post-hoc test). Representative 
semi-thin sections of PBS/BSA (C) or WNT5A (D) pre-treated L428 CAM tumours reveal minor 
hemorrhage (arrows in C) in contrast to massive bleedings (Bl in D) (left bar= 150 µm; right bar= 25 
μm) (*P < 0.05). Modified from (Linke et al, 2016b). 
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3.2.3 LEF-1 and β-catenin are important for the secreted VEGFA levels of 
cHL cells 
Since canonical WNT signalling and especially β-catenin and LEF-1 expression in 
cHLs had such a strong impact on endothelial cell behaviour the underlying 
mechanism was investigated. The hypotheses were that the differential tumour 
biology may either be due to metabolic differences of the differently treated cHL 
cells themselves, or due to differences in the secretion of pro-angiogenic factors. 
To test the first hypothesis, NMR analyses of LEF-1 and β-catenin knockdown 
cells were performed (Appendix Figure A-48). However, these data revealed no 
major differences in content of metabolites, suggesting that the metabolic rates did 
not change significantly by LEF-1 or β-catenin knockdown.  
The second hypothesis would suggest that LEF-1 and β-catenin knockdown cells 
secreted less and WNT5A pre-treated cells more pro-angiogenic factors than the 
control cells. One factor that can act as sprouting and lumen formation promotor 
on endothelial cells is VEGFA (Neufeld et al, 2001). ELISA assays of L428 and 
KM-H2 control supernatants revealed VEGFA levels of 700 and 900 pg/ml 
respectively (Figure 40 A). Additional stimulation with WNT5A for 24 or 48 hours 
did not further increase these secretion levels (Figure 40 A). After transfection 
L428 and KM-H2 control cells secreted 500 and 700 pg/ml VEGFA respectively 
(Figure 40 B). Importantly, under LEF-1 or β-catenin knockdown the secreted 
VEGFA levels dropped to 400-500 pg/ml. Thus, LEF-1 as well as β-catenin 
expression is directly correlated with the secreted VEGFA level in cHLs. 
The additional analysis of patients’ microarray data revealed a clear connection 
between VEGFA expression and overall survival (Steidl et al, 2010a) (Figure 
40 B). While approximately 90 % of patients with low VEGFA expression survived 
10 years or longer, only 65 % with high VEGFA expression were alive after 
10 years (P=.008). Consequently cHL VEGFA expression level is directly 
correlated with patient’s survival and thus therapy success.    




Figure 40: VEGFA secreted by cHL cells is not regulated by WNT5A but by LEF-1/ β-catenin 
and high VEGFA gene expression is associated with a worse overall survival in cHL 
patients. (A) VEGFA levels of L428 and KM-H2 cells do not clearly vary after 24 or 48 hours of 
recombinant WNT5A stimulation. (B) VEGFA levels of scr si control, LEF-1 si and β-catenin si L428 
and KM-H2 cell supernatants from three independent nucleofections were measured using ELISA. 
Note the decreased VEGFA levels after LEF-1 and β-catenin knockdown. (mean ± SD, n=3). (C) 
VEGFA gene expression data obtained by Steidl et al. reveals the significantly worse overall 
survival in patients with high VEGFA levels (Steidl et al, 2010a) (mean ± SD, low, n=56; high, n=68; 










Classical Hodgkin Lymphoma (cHL) is unique with respect to the fact that the 
malignant cells, the HRS cells, form the absolute minority of cells that are defined 
as the ‘tumour mass’ (Aldinucci et al, 2010). The infiltration with immune cells 
provides essential survival signals for HRS cells (Küppers, 2009; Liu et al, 2014), 
and it can be speculated that other mechanisms that control tumour maintenance 
and progression are as well regulated by interactions between HRS cells and their 
neighbouring cells, including the vascularized stroma.  
In this thesis, it has been shown that cHL cell lines are characterized by a 
remarkable migration potential which is reflected in the efficient amoeboid type of 
cell migration. This cellular motility is regulated by non-canonical WNT5A and 
basal canonical WNT signalling. In addition, angiogenesis assays could 
demonstrate that cHL cells are able to induce vessel sprouting and tube formation 
of endothelial cells that also depend on cHL WNT signalling. Finally, the impact of 
WNT signalling was confirmed in in vivo assays and by patient’s gene expression 
data thereby implying a role for WNT signalling in cHL progression. 
4.1 High migration rates are a feature of cHL cells 
HL dissemination is correlated with increased mortality rates (Böll et al, 2013; 
Guermazi et al, 2001; Introcaso et al, 2008). In HL extra-nodal involvement is seen 
in 10-15 % of all HL cases (Guermazi et al, 2001). Meanwhile evidence has 
accumulated that HL dissemination occurs by haematogenous and lymphatic 
spread (Gharbaran et al, 2014). Although the mechanisms for cHL dissemination 
mostly remained to be studied, this thesis provides a first detailed description of 
cHL cell movements as well as insights into underlying signalling cascades. 
One general consensus for lymphoma dissemination is the similarity to the original 
lymphocyte tissue-specific homing patterns. B-cells need to modify their homing 
signature depending on their present maturation stage. Thus, sites of B-cell 
dissemination might be predictable with special regard to the originating B-cell 
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stage (Cyster et al, 2002). Currently two homing receptors are discussed to play a 
role in lymphoma dissemination: CCR7 and α4β7. There are observations that, for 
example, subsets of MCLs express the intestinal homing receptor α4β7 like naïve 
B-cells and are associated with a multifocal involvement of the gastrointestinal 
tract while primary MCLs with only nodal involvement lack α4β7 expression (Pals 
et al, 1994; Geissmann et al, 1998). In addition expression of the receptor 
chemokine (C-C Motif) receptor 7 (CCR7), which is required for B-cell entry into 
secondary lymphoid tissues, is down-regulated during plasma cell differentiation 
and is also not detected in Multiple Myeloma (Trentin et al, 2007). In contrast CLLs 
and MCLs with high CCR7 expression also show widespread nodal dissemination 
(Lopez-Giral et al, 2004). Interestingly, also cHL but not NLPHL cells express high 
levels of CCR7 but lack the expression of the corresponding ligands (Höpken et al, 
2002). In addition, microarray data from Brune et al. show that the CCR7 
expression of HL cells is even higher than in physiological B-cells (Appendix; 
Figure A-49) (Brune et al, 2008). Thus the CCR7 overexpression of cHL cells 
might be one explanation why HRS cells are found in the interfollicular zone of 
lymph nodes and not at their original site of derivation, the germinal centres. 
Nevertheless Höpken et al. already discussed the limitations of this dissemination 
pattern hypothesis: HRS cells in the follicular mantle zone also express CCR7 thus 
implying that other interactions might also contribute to the distribution of tumour 
cells (Höpken et al, 2002). Consequently, cHL dissemination patterns might be 
regulated by additional chemokines, chemokine receptors, pathway deregulations 
or crosstalks like WNT signalling.   
This thesis provides a more detailed analysis of cHL cell movements in a CCL19 
gradient over the time for the first time. The amoeboid type of migration is reflected 
in the high cHL cell migration rates compared to BL, DLBCL and even MCL cell 
lines. Since the cHL cell lines L428, KM-H2 and L1236 have been established 
from late-stage/relapsed HL patients, it could be suggested that highly efficient 
motility processes might also be linked to advanced cHL stages. HL cells 
represent a highly heterogeneous group of cells concerning the classes of cell 
movements, with constantly turning cells, as well as slow to fast migrating cells 
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that cover short to longer distances. The characteristic formation of short blebs 
and long protrusions will have to be investigated further with special regard to its 
precise function e.g. for orientation or obstacle assessment by the cHL cell. 
Further investigations should also clarify the dynamics of bleb formations and the 
responsible molecular composition.  Moreover, cHL cell movements appear to be 
also influenced by other surrounding cHL cells that seem to affect the direction of 
movements occasionally through cell-cell contacts. Those intercellular 
mechanisms need to be analysed in future studies regarding their function and 
modifying capacity for cHL group movements because they might also contribute 
to the distribution of tumour cells as discussed by Höpken et al.(Höpken et al, 
2002)  
Although chemokine receptor expression patterns can determine the direction of 
movements a highly dynamic actin cytoskeleton is a first indispensable 
prerequisite for amoeboid cell migration (Miao et al, 2003; Yamazaki et al, 2005). 
Therefore, there is a need in understanding signalling cascades that contribute to 
the high dynamics of cHL cell movements. Next to the analysed cHL movement 
patterns and characteristics this study aimed at investigating the WNT signalling 
cascade that contributes to cHL cell motility by providing and preserving high actin 
dynamics. 
4.2 WNT signalling is a regulator of cHL cell migration and 
invasion 
Notably, WNT signalling has been identified as important regulator of cHL cell 
motility. As highlighted in the introduction, CLL cells are characterized by an 
aberrant LEF-1 expression and their migration is strongly associated with 
WNT/PCP signalling (Erdfelder et al, 2010; Gutierrez et al, 2010; Kaucká et al, 
2013). These studies on CLL motivated us to investigate the underlying signalling 
mechanisms also in cHLs. Herein, the new role of canonical and non-canonical 
WNT signalling is highlighted as autocrine pathways for cHL cell motility and 
invasion.  
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4.2.1 Autocrine secreted WNT5A is an enhancer of cHL cell motility 
One major finding of this thesis is that autocrine WNTs and especially WNT5A are 
major drivers of HL cell migration and invasion in vitro. WNT5A positively affects 
general motility as well as the directed migration towards a chemokine and 
invasion rates.  
WNTs have been identified as key players in early stages of haematopoiesis 
underlining the physiological role of WNTs in B-cell differentiation (Malhotra et al, 
2008; Reya et al, 2000). Nevertheless, the role of WNTs for mature B-cells during 
the germinal centre reaction is still unclear. Germinal centre B-cells are the 
proposed cells of origin of cHL and aggressive NHLs like BLs or DLBCLs. 
Interestingly, WNT5A secreted by follicular dendritic cells is able to protect 
germinal centre B-cells from apoptosis thus permitting survival and maturation 
(Kim et al, 2012). Whether WNT5A might also affect motility of B-cells during the 
germinal centre reaction has not been investigated yet. Our data on the role of 
WNT5A in HLs would support the view that, for example, cHL cells might be able 
to create a corresponding morphogen gradient which thus supports the spread 
from the germinal centre to interfollicular sites and functional neighbouring lymph 
nodes. The herein described aberrant expression of WNT5A is a new feature of 
cHL cells.  
In CML WNT5A signalling maintains CML survival upon Bcr-Abl inhibition (Gregory 
et al, 2010). In addition, cell survival of B-cell precursor acute lymphoblastic 
leukaemia is enhanced by WNT5A  supporting the view of WNT5A as a proto-
oncogene (Thiago et al, 2010). However, it also has to be noticed that under 
certain conditions WNT5A can act as a tumour suppressor (Roman-Gomez et al, 
2007). The discovery of two WNT5A isoforms with different functions on tumour 
cells might be one assumption to explain the diverse and context-dependent role 
of WNT5A in cancer cells (Bauer et al, 2013). However, all these analysis were 
focused on cell survival but not cell migration behaviour.  
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In CLL, an indolent NHL, PCP WNT signalling was shown to be important for CLL 
cell motility although the ligands are still unknown (Kaucká et al, 2013). In breast 
cancer WNT5A showed highest expression in the invasive mammary carcinoma 
cells thus serving as prominent factor for breast cancer invasiveness (MacMillan et 
al, 2014). Accordingly, our data for cHLs demonstrates how enhanced autocrine 
WNT5A secretion increases cellular motility including blebbing and velocity thus 
probably facilitating tumour progression and relapse. Therefore, it is reasonable to 
suggest that WNT5A signalling changes pathophysiological parameters of cHL 
cells to a more aggressive behaviour. 
In cHL cells WNT5A mediated cell migration and invasion through FZD5, DVL3 
and RHOA activation. Thus, the observation of FZD5-mediated WNT5A effects in 
cHL cells corresponds well with the recent description of a high WNT5A-FZD5 
binding affinity (Dijksterhuis et al, 2015). Nevertheless also other WNTs might be 
able to bind to FZD5 in cHL cells, and also WNT5A might be able to interact 
additionally with other FZDs. More comprehensive expression studies of all 
autocrine WNTs as well as receptors will be needed for clarification. However, 
WNT10A, WNT10B and WNT16 could not enhance cHL cell migration under the 
applied experimental conditions. Mechanistically, DVL proteins have already been 
proven to connect FZD/G-protein signalling thereby acting as central regulators of 
the signalling cascade (Kilander et al, 2014). The DVL isoforms DVL1, DVL2 and 
DVL3 are apparently able to integrate multiple WNT signals but are also 
specifically able to mediate branching of WNT signalling as shown best in 
Xenopus laevis (Gentzel et al, 2015). Nevertheless little is known about the distinct 
functions of the different DVL variants in cancer. In all analysed cHL cell lines the 
interaction of WNT5A and FZD5 involves DVL3 as central mediator for cHL cell 
migration. Importantly, all three DVL isoforms are constitutively active in the 
investigated cell lines. Interestingly, the DVL2 activation is independent of 
porcupine, which suggests that DVL2 is independent of WNT signalling in cHL 
cells. Considering the knockdown experiments and overexpression of a dominant 
negative DVL3 variant DVL3 most probably has a dominant role in WNT5A-
mediated cHL cell migration. Recently increased expression of DVL1 and DVL3 
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could be shown in brain metastases of lung cancer thus connecting DVL 
expression with tumour progression (Kafka et al, 2014). Consequently, DVL3 
activation in cHL cells might be also important for lymphoma progression and 
future clinical studies will have to clarify whether aberrant DVL3 expression or 
activation is involved in cHL progression. 
Moreover, the thesis shows the essential contribution of RHOA activation to the 
motility and amoeboid type of migration of cHL cells. It is well-known that 
amoeboid migration depends on RHOA/ROCK signalling as prerequisite of motility 
rather than on Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small 
GTP Binding Protein Rac1) (RAC) (Sahai & Marshall, 2003). Nevertheless, it 
cannot be excluded so far that cHL cell movements also require activation of RAC 
or Cell Division Cycle 42 (CDC42). Several cancer cells are able to switch 
between the RAC-dependent mesenchymal and the RHOA-dependent amoeboid 
type of migration depending on the particular circumstances (Friedl, 2004). Similar 
mechanisms should also be analysed for cHL cells. Comparable activity 
measurements as performed for RHOA (chapter 3.1.10) will also be of interest for 
RAC and CDC42 with porcupine-inhibited or WNT5A-stimulated cHL cells. In 
addition, the effect of CCL19 on small GTPases like RHOA, RAC or CDC42 will 
have to be investigated in comparison to WNT5A stimulation. 
Another approach might be the analysis of potential WNT5A target genes. 
WNT5A-mediated PCP signalling was of central interest in this thesis, 
nevertheless, it cannot be excluded that WNT5A can also activate calcium-
dependent NFAT-mediated WNT target genes or C-Jun N-Terminal Kinase 1/JUN 
(JNK/JUN)-mediated target genes. In addition the direct regulation of small 
G-proteins by WNT5A could not be proven in qRT-PCR assays (Zaunig, 
unpublished thesis). Nevertheless, it will be subject to future assays to test 
whether WNT5A might be able to regulate other targets e.g. of the canonical WNT 
pathway. Therefore, RNA interference, specific inhibitors or genome editing could 
be applied to test, for example, JNK-regulated gene expression changes following 
WNT5A signalling.  
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4.2.2 Canonical WNT signalling modifies especially collagen-induced cHL 
motility 
In addition to the WNT5A-mediated PCP signalling of cHL cells also canonical 
WNT signalling has been studied. Since WNT5A was unable to rescue porcupine 
inhibited cHL cells completely and stimulation with supernatant of cHL cells could 
further increase the already existing basal nuclear fraction of β-catenin, the 
rationale of an autocrine canonical WNT signalling in cHL cells evolved. Canonical 
WNT signalling of cHL cells has been blocked at different levels of the pathway, 
which constantly resulted in reduced chemotactic migration in Boyden chamber 
assays. Interestingly, the migratory deficiencies induced by LEF-1- or β-catenin-
knockdown, were even more obvious in invasion assays with type--collagen, and 
the most obvious in 3D-chemotaxis chambers, where the cells are completely 
embedded in type--collagen. These observations suggest a specific role for 
canonical WNT signalling in collagen-mediated cHL cell movements, and indicate 
functions for the expression of molecules that interact with collagen, e.g. of the 
Discoidin Domain Receptor Tyrosine Kinase 2 (DDR2) signalling pathway (Afonso 
et al, 2013). DDR2 is a collagen receptor which is specifically activated by type- 
and type--collagen (Vogel et al, 1997; Shrivastava et al, 1997). Renné et al. 
showed that approximately 65 % of patients with the nodular sclerosis and 25 % 
patients of the mixed cellularity subtype express DDR2 (Renné et al, 2005). 
Conceivable LEF-1/β-catenin targets might comprise the DDR2 receptor regulation 
pathway or direct signalling members and need to be investigated.  
In a medical doctor thesis it was analysed whether LEF-1/β-catenin regulate PCP 
target genes like WNT5A or FZD5 directly but no correlation has been found so far 
(Harenberg; unpublished thesis). Nevertheless LEF-1/β-catenin target genes might 
directly or indirectly affect general secretion mechanisms. To test this hypothesis a 
general secretome analysis of untreated cHL cells in comparison to porcupine-
inhibited, LEF-1/β-catenin knockdown and WNT5A-stimulated cHL cells would 
clarify the effect of WNT signalling on the cHL secretome. 
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4.3 cHL cells possess pro-angiogenic properties that rely on 
WNT signalling 
In this thesis the angiogenic potential of cHL cells has been assessed with various 
in vitro assays and the in vivo CAM assay. Angiogenic properties have not yet 
been evaluated for cHL cells, although such studies including CAM assays had 
been proposed by Marinaccio et al. (Marinaccio et al, 2014). Importantly, cHL cells 
are able to induce the capacity of endothelial cells to sprout and to form tubes thus 
promoting angiogenesis processes. Moreover, in our group it has been shown, 
that cHL cells can also attract endothelial cells and increase their migration 
capacities (Harenberg; unpublished thesis). 
The dissemination patterns of HL have been discussed since the 1960s but initially 
focused on the lymphatics as route for the spread to contiguous lymph node 
chains (Rosenberg & Kaplan, 1966; Kaplan, 1971; Smithers et al, 1974; Mann et 
al, 1986). The involvement of the spleen and other distant tissues like the bones 
has been discussed as hints for the additional haematogenous spread of HL 
(Horan, 1969; Halie et al, 1972b; Vockerodt et al, 1998). In 5-10 % of HL cases 
dissemination occurs via the haematogenous route (Guermazi et al, 2001). 
Moreover, the presence of abnormal cells, that are believed to be circulating HL 
cells by now, supports the view of a haematogenous route in addition to the 
spread via the lymphatics (Halie et al, 1972a; Zucker-Franklin et al, 1983; Sitar et 
al, 1994). Furthermore, the cHL cell line L1236 has been established from 
circulating peripheral blood mononuclear cells of an advanced stage HL patient 
(Wolf et al, 1996; Kanzler et al, 1996a). 
Therefore, it is reasonable to conclude that HL progression involves interactions 
with endothelial cells as well as manipulations of endothelial cell behaviour. The 
migration and adhesion of lymphoma cells to HUVECs is a model to study the 
dissemination process of the tumour cells, which has a major impact on the 
outcome of the disease. Although not investigated for cHL, the adherence to HEVs 
has been associated with the dissemination potential of Non-Hodgkin lymphomas, 
which has been confirmed in lymphoma mouse models (Stauder et al, 1993; 
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Bargatze et al, 1987). Therefore, endothelium-mediated chemotaxis and 
adherence of lymphoma cells to endothelial cells can be regarded as parameters 
for cHL progression. Given this, the question arises if cHL cells gain an additional 
benefit from their proximity to endothelial cells, despite the apparent induction of 
angiogenesis and facilitation of dissemination. One hint comes from the studies by 
Fhu et al. (Fhu et al, 2014), who have shown that cHL cells actively secrete 
lymphotoxin-α, which caused the upregulation of adhesion molecules in 
endothelial cells thereby recruiting CD4+ naïve T-cells. This suggests that 
endothelial cells can actively participate in the recruitment of lymphoma-supporting 
T-cells, and thereby shape the cHL microenvironment towards a pro-tumourigenic 
niche. The secretion of VEGF-A by cHL cells additionally fits into this scenario, but 
suggests an additional function for endothelial cells in cHL progression. In a 
previous study, 70.6% (41/61) of immunostained cHL samples were positive for 
VEGF-A (Doussis-Anagnostopoulou et al, 2002). The reevaluation of published 
patient’s data shows that high VEGF-A levels correlate with a significantly worse 
overall survival (Figure 40 C) (Steidl et al, 2010a). In this thesis evidence is 
provided for WNT-regulated signalling mechanisms of VEGF-A secretion in cHL 
cells. VEGF-A has been identified as a factor secreted in a LEF-1- and β-catenin-
dependent manner by cHL cells. Nevertheless, it cannot be ruled out that the 
secretion of other endothelial modulating factors is regulated by canonical WNT 
signalling in cHL cells. To assess the complete effects of LEF-1 and β-catenin 
signalling also in relation to WNT signalling interventions in cHL, a broad 
secretome analysis must be performed in future experiments. However, it cannot 
be excluded that autocrine secreted WNTs that activate WNT signalling in cHL 
cells also influence endothelial cells. Activated canonical WNT signalling in 
HUVEC cells has already been proven to induce endothelial cell invasion and thus 
may contribute to the complex effects of cHL supernatants on endothelial cells 
(Planutiene et al, 2011). 
In this thesis HUVECs were used as model system to analyse the influence of cHL 
cells on blood vessel structures. However, it is obvious that the effect of cHL cells 
on lymphatic vessels has to be clarified by using, for example, lymphatic 
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microvascular endothelial cells (LECs). It will be of interest whether cHL cells are 
also able to induce lymphangiogenesis or whether their influence is specifically 
concentrated on endothelial cells.   
In summary, autocrine activated WNT signalling contributes to the pro-angiogenic 
properties of cHL cells at least by mediating VEGFA secretion through 
LEF-1/β-catenin. Interestingly, cHL cells are able to migrate towards ECs in 
response to chemokines and also attract ECs via VEGFA secretion. Importantly, 
for both processes particularly canonical WNT signalling in lymphoma cells is a 
prerequisite. 
4.4 In vivo Lymphoma engraftment is significantly affected by 
both, canonical and non-canonical, WNT signalling 
In addition to the autocrine role of WNT5A and canonical WNT signalling in the 
regulation of cHL cell migration, invasion and adhesion evidence accumulated for 
additional paracrine effects of WNTs. In the chick chorio-allantoic assay lymphoma 
development is WNT dependent. Inhibition of cHL WNT secretion and the 
canonical WNT pathway impaired lymphoma outcome while WNT5A stimulation 
increased lymphoma development. Regarding the in vitro analyses of cHL cell 
interaction with HUVECs WNT signalling might also be important in the regulation 
of vessel integrity in lymphomas. Vascularization of lymphoma depends on 
canonical WNT signalling and also on WNT5A.  
Recently, angiogenic activity of WNTs has been observed in non-small-cell lung 
cancer (NSCLC) and malignant melanoma (Yao et al, 2014; Ekström et al, 2014). 
In NSCLC high WNT5A expression is associated with higher microvessel density, 
vascular mimicry and worse clinical outcome (Yao et al, 2014). However, in 
absence of reliable mouse models for HL  we used the CAM assay to assess cHL 
engraftment in vivo. The massive bleeding in WNT5A-stimulated cHL is obviously 
a result of vessel disruption illustrating the high vessel dynamics within the 
lymphoma. Whether the vessel destructive activity is directed against pre-existing 
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or newly generated vessels still needs to be investigated. Nevertheless, it is 
reasonable to conclude that WNTs affect both angiogenesis and vessel integrity in 
cHLs. The hemorrhages may open up an additional haemogenic route for 
dissemination.  As cHL cells are characterized by an amoeboid migration it is 
interesting to note that also several non-small-cell lung cancer cell lines are 
characterized by this migration type (Carragher et al, 2006). Although in vitro 
WNT5A is unable to stimulate migration and proliferation of endothelial cells 
(Samarzija et al, 2009) and WNT5A stimulation could not enhance VEGFA 
secretion, the data suggest that WNT5A is not only promoting adhesion to 
endothelial cells (HUVEC), but it may also induce new vessels. In malignant 
melanoma it has been shown that the secretion of pro-angiogenic factors like 
VEGFA or IL-6 is mediated by WNT5A (Ekström et al, 2014). As HL cells secrete 
IL-6 it is reasonable to study the interaction of this cytokine with WNTs in the 
subsequent assays. 
Additionally, inhibition of canonical WNT signalling reduced lymphoma outcome, 
namely lymphoma size and hemorrhages, in vivo. Obviously, parts of these 
observations can be explained by reduced VEGF-A secretion as observed after 
LEF-1 and β-catenin knockdown. However, as discussed in chapter 4.4, other 
targets of canonical WNT signalling of cHL cells might contribute to the WNT-
dependent lymphoma outcome in cHL. As inhibition of canonical/non-canonical 
WNT signalling did not inhibit cHL cell proliferation nor did LEF-1/β-catenin 
knockdown change metabolite’s turnover a different lymphoma outcome due to 
proliferation seems not very likely. But another hypothesis might involve the 
affected chemotaxis and invasion of cHL cells after WNT signalling inhibition. It will 
have to be tested whether the reduced ability to adhere and invade impedes 
already the initial settling on the CAM and the subsequent invasion through the 
chorionic epithelium. In that case WNT-inhibited lymphomas would have a survival 
disadvantage from the very beginning of tumour development that could probably 
account for the drastic differences in tumour outcome after four days of tumour 
growth on the CAM. In support of this scenario also the impaired chemotaxis of the 
cHL cells themselves towards CAM blood vessels could contribute to worse 
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nutrient supply of the tumour and therefore limit tumour growth. Those 
considerations could be investigated by more comprehensive CAM assays at 
different time points and by using immunohistochemistry, electron microscopy as 
well as Micro-CT.    
4.5 Therapy of cHL and future prospects 
Besides the advantages of CAM assays to monitor cHL engraftment in vivo there 
are obvious limitations before these results can be extrapolated to human beings. 
In order to bridge the gap towards the clinic we cooperated with the working group 
of Prof. Klapper (Section Haematopathology, UKSH Campus Kiel) during the time 
of the thesis. Based on the promising results from the analysis of HL patient’s 
microarray data of publically available data bases, we decided to stain tissue 
microarrays of HL patients for LEF-1. In total 27 cHL samples have been stained 
whereof 18 samples were of the nodular sclerosis type and 9 of the mixed 
cellularity type. LEF-1 positive HRS cells were found in 3/9 (33 %) mixed cellularity 
type and 1/18 (6 %) nodular sclerosis subtype of cHL (Linke et al, 2016a, 
submitted) (Figure 41). Since LEF-1 expression within the HRS cells is observed 
in a proportion of mixed cellularity type cHL canonical WNT signalling might play a 
role for that subgroup of patients. 
In general the therapy of cHL comprises chemotherapeutic regimens, but has not 
until recently focused on the lymphoma-endothelium interplay as a potential target. 
Currently, a single group study (NCT00722865) investigates the effects of 
anti-VEGFA monoclonal antibodies (bevacizumab) in combination with the ABVD 
chemotherapeutic regimen, and may provide new insights into the clinical use of 
bevacizumab for cHL by the end of 2016. In an earlier study the effects of 
bevacizumab in five patients with refractory and multiple-relapsed Hodgkin 
lymphoma were investigated (Reiners et al, 2009). The combined treatment of 
bevacizumab with the chemotherapeutic agent gemcitabine led to partial or 
complete remission in 3 of 5 patients. Biological effects like tumour size or serum 
CD30 levels were affected under bevacizumab therapy only in patients with 
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reduced serum VEGFA levels. This first promising result needs to be further 
investigated in larger studies in comparison with a control group. Our 
immunohistochemistry results would additionally suggest a further discrimination 
between the nodular-sclerosis and mixed cellularity subtypes of cHL for the 
stratification of such studies. 
 
Figure 41: Positive LEF-1 staining was found in 3/9 (33 %) mixed cellularity cHL samples. 
Immunohistochemical staining of LEF-1-positive (left) and negative (right) HRS cells of mixed 
cellularity type patients. HRS cells show nuclear LEF-1 staining only in the left case (inlet).In some 
bystander cells also the nuclear LEF-1 staining can be observed. Adopted from (Linke et al, 
2016a). 
Another up-to-date therapy strategy concentrates on the highly important cHL 
microenvironment (see chapter 1.1.3) by targeting immune checkpoints. Anti- 
programmed cell death 1 (PD-1) antibodies like nivolumab abolish the lymphoma-
mediated T-cell blockade thereby inducing T-cell-anti-tumour-activity (Okazaki & 
Honjo, 2007; Ribas, 2012). Nivolumab treatment of cHL patients with several 
therapy failures, including relapses after autologous stem-cell transplantation and 
BV treatment, still caused a remarkable progression-free survival rate of 86 % 
(95 % CI 62–95) at 24 weeks (Ansell et al, 2015). As consequence of these 
successful and new approaches new trials plan to combine BV-based treatment 
strategies with other drugs like nivolumab to treat HL patients with high response 
rates but manageable drug toxicities thereby probably changing the standard of 
care of HL patients (Stathis & Younes, 2015). Of note, drugs targeting the HRS 
cells’ motility or migration capacity are not yet discussed but might also be 
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candidates for combination therapies as it is increasingly discussed also as add-on 
to standard therapies for solid cancers (Wells et al, 2013). Porcupine might be, for 
example, one interesting target since an enzyme might be easier to address than 
protein-protein interactions and an additional combination with the anti-CD30 
antibody would assure extra-specificity. Targeting molecular mechanisms involved 
in cHL chemotaxis might therefore be used to target the cHL dissemination 
potential as add-on therapy. 
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5. Summary and Conclusions 
Cancer cell motility is one feature associated with cancer progression, metastasis 
and therapy resistance. Especially movements towards endothelial cells and the 
general lymphoma-endothelial interplay are of particular interest for an improved 
understanding of lymphoma dissemination. In this thesis the motility of cHL cells 
and their ability to influence endothelial cells were investigated with special regard 
to the WNT signalling.    
Amoeboid HL cell migration, invasion and adhesion capacities depend specifically 
on autocrine WNT signalling. Therefore, a model is proposed in which cHL cells 
secrete WNT ligands at least partly on EVs to induce autocrine signalling 
cascades in cHL cells. One very important autocrine function has been identified 
for the WNT5A-FZD5-DVL3-RHOA signalling cascade that is central to modify the 
cHL cytoskeleton. Secreted WNT5A of cHL cells is able to induce cHL cell 
migration and invasion by enhancing motility parameters. While WNT5A protein 
was present on EVs of cHL cell lines evidence accumulated that cHL cells also 
secrete at least one not yet identified canonical WNT ligand to sustain a basal 
canonical WNT pathway activity in the cells. Canonical WNT signalling of cHL cells 
via β-catenin and LEF-1 mediates cHL cell migration possibly through target genes 
involved in cytoskeleton rearrangement and perhaps in the regulation of the non-
canonical pathway. Since canonical WNT signalling inhibition had the strongest 
effects in collagen-based assays it is also reasonable to investigate target genes 
in collagen-induced chemotaxis signalling cascades.      
Furthermore, by using a chick CAM xenograft cHL model a new paracrine mode of 
interaction of cHL cells with the vasculature has been revealed. Inhibition of WNT 
secretion reduces cHL lymphoma size and affects the whole vasculature of the 
tumours. While additional WNT5A stimulation further increased tumour 
hemorrhages, inhibition of canonical WNT signalling caused a remarkable 
impairment of the lymphoma vasculature network. These pro-lymphomagenic 
effects further strengthen the important role of WNT signalling for HL 
pathophysiology. One possible mechanistic explanation of the paracrine WNT 
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effect is the regulation of VEGFA secretion. LEF-1 and β-catenin but apparently 
not WNT5A mediate the secretion of VEGFA thus influencing endothelial cell 
migration, sprouting and vessel tube formation. Since LEF-1 expression can be 
observed in 33 % of mixed cellularity type HL and high VEGFA expression is 
associated with a worse overall survival in cHL patients, the data support the 
concept that basal canonical WNT signalling plays a critical role for lymphoma 
progression in a subset of cHL. Whether targeting WNT or VEGFA signalling might 
become a promising target for the treatment of patients will remain to be 
elucidated in corresponding clinical trials. An overview scheme of all herein 
analysed WNT effects is provided in Figure 42. All in all, a deeper understanding 
of the regulators of lymphoma dissemination may provide new targets to prevent 
progression, and failures from currently used treatment modalities. WNT signalling 
might be a promising diagnostic and therapeutic target for cHL in late stages and 
relapses, and should be investigated in corresponding clinical trials. 
 
Figure 42: Scheme of autocrine WNT5A signalling loop and canonical WNT signalling in 
cHLs. The scheme is composed of porcupine-dependent WNT secretion and autocrine WNT5A 
signalling via FZD5, DVL3 and RHOA to stimulate cHL migration as well as autocrine canonical 
WNT signalling that stimulates migration possibly through target gene regulation but also VEGFA 
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Figure A-43: Additional data to time-lapse microscopy of Wnt-C59, Box5 or WNT5A pre-
treated L428 cells using the IBIDI 3D chemotaxis chamber. (A) Exemplary trajectories of 50 
cells per experiment at the starting point and after 6 hours are shown in coloured lines. (Yellow 
square visualizes the area observed in Figure 17). (B) Complete heat map shows all fingerprints of 
DMSO (light blue), Wnt-C59 (black), Box5 (green) or WNT5A (orange)-treated L428 cells without 
clustering (addition to Figure 19).  





Figure A-44: KM-H2 migration depends on FZD5 and Box5 abolishes DVL3 activation in HL 
cell lines. (A) Migration and Western Blot were performed 48 hours after FZD5 knockdown in 
KM-H2 cells. For protein detection specific antibodies against FZD5 and against tubulin as loading 
control were used (mean ± SD, n=3, Mann Whitney test, **P < 0.01). (B) Western Blot shows L428 
cells stimulated with 100 ng/ml recombinant WNT5A for the indicated time intervals. Note the 
increasing activation of DVL3 during the first 30 minutes. (C) Western Blot shows DMSO or Box5 
(100 μM) pre-treated L428, KM-H2 and L1236 cells after stimulation with 100 ng/ml recombinant 
WNT5A for 10 minutes. For protein detection (B, C) specific antibodies against DVL1, DVL2, DVL3 
and against tubulin as loading control were used. Modified from (Linke et al, 2016b).   






Figure A-45: Treatment with XAV939 or PF670462 abolishes nuclear β-catenin fraction. 
Western Blot was performed with cytosolic and nuclear fractions of L428 cells stimulated with 
wildtype, WNT3A or WNT5A L-cell conditioned medium (CM) after treatment with XAV939 (A) or 
PF670462 (B). For protein detection specific antibodies against β-catenin and against HDAC as 
nuclear control and HSP90 as cytosolic control were used.  
 
This immunoblot is a control for the efficacy of the XAV939 and PF670462 





Figure A-46: TCF RNA and protein level are not influenced by the LEF-1 knockdown. qRT 
results of L428 cells as well as KM-H2 cells with transient (A; C) and stable (B; D) LEF-1 
knockdown show no strong influence of LEF-1 knockdown on TCF7, TCF7L1 or TCF7L2 gene 
expression. Only KM-H2 cells with stable LEF-1 knockdown show slightly increased TCF7 gene 
expression levels. (mean ± error; KM-H2 LEF-1 si n=1; L428 LEF-1 si, L428 LEF-1 sh KM-H2 
LEF-1 sh n=3) (E) Western Blot of L428 and KM-H2 cells shows no influence of the LEF-1 
knockdown on TCF3 protein (protein of TCF7L1) level and just slight effects on the TCF4 (protein 
of TCF7L2) level in KM-H2 LEF-1 knockdown cells. For protein detection specific antibodies 
against LEF-1, TCF3, TCF4 and against GAPDH as loading control were used.  
 
This immunoblot serves as control of the other TCF expression levels for LEF-1 





Figure A-47: Cell tracks of KM-H2 LEF-1 si and β-catenin si cluster separately from scr 
control cells. Heat map displays the results of the hierarchical clustering of movement patterns of 
scr si, LEF-1 si and β-catenin si KM-H2 cells based on shape fingerprints according to the form and 
length of each track. The x-axis of the heat map corresponds to the internal distances within single 
tracks, with short distances mapped to the left and longer distances to the right. The colour of the 
heat map tiles represents the number of counts for specific distances per track ('square root 
transformed' to enhance contrast). Experimental group membership is encoded by colours on the 
left side of the heat map with black (scr si), green (LEF-1 si) and orange (β-catenin si). From (Linke 
et al, 2016a). 
This heat map shows the clustering scr si, LEF-1 si and β-catenin si KM-H2 cell 











Valid Missing Total 
N Percent N Percent N Percent 
40 88,9 5 11,1 45 100,0 
a. Protein factor = 1 
b.  Squared Euclidean Distance used 
c. Average Linkage (Between Groups) 
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Figure A-48: Metabolites of L428 and KM-H2 pGIPZ LEF-1 sh cells are not different from 
control cells. Metabolomics NMR analysis data from three independent experimental sets 
(KM-H2/L428; parental, LEF-1 sh, ns ctr) were normalized by total protein amount in each sample 
and their metabolic profile (based on 25 metabolites) was analysed using Cluster analysis 
(Euclidean distance; Ward´s method; link distance scaled as percentage of maximal link distance). 
The LEF-1 knockdown does not cause any obvious change in the metabolism of cHL cell lines KM-
H2 and L428. BL cell line BL41 was used as an external control. From (Linke et al, 2016a). 





Figure A-49: CCR7 expression is increased in cHL patients compared to physiological B-cell 
subsets. CCR7 expression is high in several HRS patients’ samples (no. 6). CCR7 expression 
data was obtained by single HRS cell analysis by Brune et al. (Brune et al, 2008) (mean of single 
patients’ data; No.1: centroblasts n=5; No.2: memory B-cell n=5; No.3: naïve pre-germinal centre 






Video 1: L428 cells, DMSO-treated for 72 hours 
Video 2: L428 cells, Wnt-C59-treated for 72 hours 
Video 3: L428 cells, Box5-treated for 24 hours 
Video 4: L428 cells, WNT5A-stimulated for 24 hours 
Video 5: KM-H2 cells, scr siRNA 
Video 6: KM-H2 cells, LEF-1 siRNA 

















Cell track analysis using shape fingerprint descriptors by Manuel M. Nietert  
To derive a condensed depiction for the observed track space, we performed an 
analysis using 2D shape fingerprints, which were derived from the internal 
distance distribution for each track, like it is common for the shape description of 
chemical compounds in cheminformatics (Schneider et al, 1999). 
Software 
We used KNIME version 2.11.3 (Berthold et al, 2007) to organize the analysis of 
cell tracks and perform preprocessing, the final analysis steps like deriving the 
fingerprints, hierarchical clustering and plotting where done with corresponding 
R-nodes in KNIME using R version 3.0.2. (Development Core Team, R: A 
language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria, 2011). 
Deriving cell track fingerprints 
To derive the individual track fingerprint we implemented the following steps as an 
R function: 
1. Generating intra-track distance matrices per track →we transformed the 
xy-coordinate collection for each track into an individual distance matrix 
representation, thus mapping the occurring internal distances of each track. 
2. Estimating the binning parameters → To achieve a comparable scaled binning 
of the resulting correlation vectors we scanned the individual track distance 
matrices for the global max distance reported, then we used the global maximum 
of intra-track distances to set the binning algorithms required max distance to be 
used for all tracks. The number of bins was set to n=100; which seems a 
reasonable choice given that 50 time steps were recorded per track and the global 




3. Deriving the shape fingerprints → The use of a binning vector function (using a 
range [0; global_max_distance], and #_of_bins = 100) allowed to transform each 
distance matrix into a correlation vector representation. For each occurring 
distance within a track the corresponding bin position to count up in the 
n-dimensional correlation vector can be simply calculated using: 
bin_position = floor((current_distance-global_minimal_distance) / (global_max_ 
distance – global_minimal_distance) * #_of_bins). 
4. Resulting correlation vector table containing fingerprints → having derived the 
shape fingerprint vector for each track we used the vector representations for our 
similarity calculations; e.g., hierarchical clustering, heat map representations 
Similarity analysis using cell track fingerprints 
We used the fingerprints to explore the track space. The analysis can be divided 
into the following sequential steps: 
1. Hierarchical clustering of the tracks → We used the fingerprints to derive 
dendrogram representations of the track space using Manhattan distance for all 
distance calculations and complete linkage method for the tree construction. 
2. Identifying the main clusters → we used the cut-tree function to derive the main 
clusters in track space. 
3. Identifying cluster representatives → for each cluster we derived the 
representative track by identifying the track fingerprint with the smallest cumulative 
distance to the other cluster members. 
4. Mapping tracks from different experiments to the clusters → after successful 
inspection of the cluster representatives to represent the required distinction level, 
we mapped the tracks respective experiment type to the dendrogram leafs. 
Extracting the cluster group members we thus could derive the count of the tracks 
per experiment per cluster. Finally, scaling the count per experiment resulted in 
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